index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
146,nras,protein,,nras,uniprot,p01111,cytoplasm,go:0005737,braf,protein,,braf,uniprot,p15056,cytoplasm,go:0005737,positive,d,phosphorylation,,horse and human melanoma,melanoma,,"horse, human",['383'],nan,nan,"additional file 3: figure s2: supplimentary data to figure 3a and b. (a) quantification of tubulin-normalized nras, braf, mek1/2, rkip and sprouty2 protein levels in the horse and human melanoma cell lines shown as the mean ± s.e. of three independent western blots. (b) quantification of total-erk1/2-normalized p-erk1/2 levels in homel-a1 and homel-l1 cells treated with inhibitors for pi3 kinase/akt (ly294002, 50 μm) and raf kinases (l779450, 10 μm) expressed as % of dmso control. the cell lines were cultured in the presence of dmso as vehicle control or with the indicated concentrations of the inhibitors for 12 h following a 2 h serum-free preincubation and their effect on erk1/2 activation was analyzed by western blot. the mean ± s.e. of three independent western blots are shown. (pdf 75 kb)",pmc4254013,1,100,40,1,140
140,n-ras,protein,,nras,uniprot,p01111,,,stat3,protein,,stat3,uniprot,p40763,mitochondria,go:0005739,positive,d,phosphorylation,s727,mefs,fibroblast,,mouse,['33'],nan,nan,"k- or n-ras transformed mefs expressing wild type stat3 or mitochondrially-targeted stat3 behaved indistinguishably from each other in their clonogenic capacity in response to mek inhibition. however, there was a statistically significant (p<0.001 for k-ras and p<0.05 for n-ras) increase in colony forming capacity of k- or n-ras transformed mefs expressing mitochondrially-targeted s727d mutant stat3 in the presence of 50 and 100 nm pd0325901 (figure 3 and figure 4). while anchorage independent growth was still impaired in the presence of phospho-mimetic mitochondrial stat3 at high concentrations of the mek inhibitor, colony formation was inhibited only approximately 2-fold at 50 nm pd0325901, a concentration that abrogated anchorage independent growth of wild type stat3-expressing cells. together, these data show that serine 727 phosphorylated stat3 is necessary for transformation by all 3 ras isoforms, h, k and n. these data also show that the raf-mek-erk pathway, and not the pi3k pathway triggered by ras oncoproteins leads to stat3 s727 phosphorylation. moreover, these data suggest that maintenance of mitochondrial stat3 phosphorylation represents an important component of ras transformation and provision of this modification partially relieves the dependence on activated erk pathway for anchorage independent growth.",pmc3843736,1,100,40,1,140
192,ptprs,protein,phosphatase,ptprs,uniprot,q06413,cytoplasm,go:0005737,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,negative,d,phosphorylation,"y1068, y1173",a431 epidermoid carcinoma,epithelial-like,skin,human,['332'],nan,nan,"ptprs was reported to be an egfr phosphatase in a431 epidermoid carcinoma cells and head and neck cancers25,27. we observed that loss of ptprs (knockout) caused a modest but statistically significant increase in phospho-egfr at y1068 and y1173 in wild-type kras crc cell lines yet had no effect in mutant kras cell lines (fig. 6a). using hct116 parental (kras g13d/+) and the isogenic hct116 (kras −/+) cell line, we demonstrated that loss of ptprs had no or minimal effect on egfr phosphorylation in mutant kras hct116 cells following egf stimulation whereas wild-type kras hct116 (−/+) cells lacking ptprs had a more prolonged activation of phospho-egfr compared to the control cells containing ptprs (fig. 6c,d). these data indicate that ptprs may be involved in negative regulation of egfr signaling in the absence of oncogenic activation of kras in crc. since we consistently observed a significant increase in erk phosphorylation by inhibition/loss of ptprs in both mutant and wt kras cell lines, the regulation of egfr signaling appears to be not necessary for ptprs’s role in moderating erk activation. activated erk not only mediates ras pathway downstream signaling that regulates various cellular process but can also mediate feedback regulation of ras pathway32–35,47,48. we also observed ptprs ko-mediated feedback inhibition of ras-gtp expression in association with erk activation in wt kras but not mutant kras cell lines (fig. 4b). this suggests that mutation-activated ras might block feedback regulation of ras pathway activation by ptprs.",pmc6006154,1,100,40,1,140
83,gapdh,protein,,,uniprot,p04406,cytoplasm,go:0005737,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,d,binds,,mda-mb-231,epithelial,breast,human,['262'],nan,nan,"the monoclonal antibody against gapdh was purchased from epitomics (burlingame, ca). the p-erk, erk antibodies were purchased from cell signaling technology (danvers, ma). the human breast cancer cell line mda-mb-231 used was kindly provided by the chinese university of hong kong. the cancer cells were maintained in rpmi 1640 (gibco-brl, karlsruhe, germany) supplemented with 10% fetal bovine serum (paa laboratories, linz, austria), 100 u/ml penicillin and 100 mg/ml streptomycin and were cultured at 37°c in a humidified atmosphere containing 5% co2.",pmc5746140,1,100,40,1,140
193,ptprs,protein,phosphatase,ptprs,uniprot,q13332,cytoplasm,go:0005737,erk,protein,kinase,mapk1,uniprot,p28482,nucleus,go:0005634,negative,d,regulation,erk regulated genes,,any,any,any,['322'],nan,nan,the effect of ptprs ko on the expression of erk regulated genes,pmc6006154,1,100,40,1,140
81,fgf2,protein,,fgf2,uniprot,p09038,extracellular space,go:0005615,tgf-β1,protein,,tgfb1,uniprot,p01137,extracellular space,go:0005615,positive,d,activation,,,,,,['807'],nan,nan,fgf2 induces sustained activation of the ras—erk pathway and inhibits tgf-β1-induced emt.,pmc4440819,1,100,40,1,140
194,ptprs,protein,phosphatase,ptprs,uniprot,q15256,plasma membrane,go:0005886,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,de-phosphorylation,,"hct116, km12l4a",colorectal cancer,colon,human,['326'],nan,nan,"a significant number of somatic mutations in ptprs were found in our 468 tumor database, and in the dana farber crc database recently published6. the landscape of these ptprs mutations is shown in supplementary fig. 3. in order to determine if the mutations in ptprs could alter its functionality, we performed a biochemical analysis using phospho-erk and phospho-akt as readouts. we selected 7 native ptprs mutants in crc for further analysis (fig. 7a). these ptprs mutants were selected based on their frequency and the position of the mutation within specific domains in the ptprs protein structure. in addition to the native mutations, we also prepared three plasmids with deletion mutations to remove the immunoglobulin (ig) domain or the phosphatase domains (d1 and/or d2) of ptprs (fig. 7a). the hct116 (mutant kras) and km12l4a (wt kras) crispr ptprs ko cell lines that had highly elevated erk and akt phosphorylation (fig. 2c) were used here. when full-length wild-type ptprs was transfected back into the cells for 48 hours, the dramatically reduced phospho-erk and phospho-akt were observed compared to the empty vector control (fig. 7b,c), indicating the inhibitory activity of ptprs. the constructs with the appropriate ptprs mutations were then transfected into hct116 for 48 hours for western blot analysis. results show that 6 of 10 mutations tested (r714c, r1608q, r1384q, -d2, -d1&d2 and –ig) exhibited completely or considerably reduced ptprs activity compared to wild-type ptprs plasmid (fig. 7b,c). for example, two ptprs point mutations (r1608q and r1384q) showed a distinct reduction in erk de-phosphorylation (i.e. phospho-erk with the ptprs mutations compared to wild-type ptprs transfection). the levels of p-erk and p-akt seen in these mutants (lanes 7 and 12) match those of the empty vector (control, lane 1) and the truncation mutant that removes both d1 and d2 phosphatase domains (lane 10), implying that point mutations r1608q and r1384q are complete, de-activating mutations. interestingly, removal of just the d2 domain (lane 9) or of the ig domain (lane 11) appears to reduce the activity of ptprs as measured by phospho-erk levels, but is not completely de-activating, as is seen in lanes 7, 10, and 12. the remaining 4 mutations (t103i, s717f, v363i and r1091q) had only minimal or modest effects on the ptprs activity (fig. 7b,c). notably, similar results were also observed for phospho-akt in hct116 and km12l4a cell lines.",pmc6006154,1,100,40,1,140
114,m-ras,protein,,mras,uniprot,p11233,plasma membrane,go:0005886,a-raf,protein,isoform,araf,uniprot,p10398,cytoplasm,go:0005737,positive,d,binding,,yeast,neuronal,brain,mouse,['497'],nan,nan,"to elucidate the molecular mechanisms of the cellular functions of m-ras, we have screened a mouse brain cdna library by a yeast two-hybrid system and cloned cdnas of proteins that bind to a constitutively activated mutant of m-ras(g22v) (gly22 is substituted by val). these proteins include b-raf, ralgds, rgl2, af-6, and a c terminus–truncated isoform of a-raf consisting of n-terminal 186 amino acids (fig. 1 a). we designate this truncated protein da-raf1 (deleted a-raf).",pmc2064279,1,100,40,1,140
115,map4k4,protein,,map4k4,uniprot,q96kb5,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cell,go:0005623,negative,d,inhibition,,xenograft,adenocarcinoma,lung,mouse,['1020'],nan,nan,downregulation of map4k4 inhibits in vivo xenograft growth and metastasis of lung adenocarcinoma cells accompanied by suppressed erk activation,pmc5467491,1,100,40,1,140
116,map4k4,protein,,map4k4,uniprot,q9y4k3,cytoplasm,go:0005737,p38,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,positive,i,activation,,lung adenocarcinoma,epithelial,lung,human,['1016'],nan,nan,"identification of downstream signaling mediators of map4k4 is crucial for understanding the mechanisms underlying map4k4 regulation of lung adenocarcinoma cells. it has been shown that map4k4 can induce erk, jnk, and p38 activation in tnf‐α‐induced signaling (bouzakri and zierath, 2007; bouzakri et al., 2009; tesz et al., 2007). whether these kinases function as map4k4 downstream effector in lung adenocarcinoma remains to be determined. to gain initial clues, we compared cellular map4k4 levels to the activation status of mapk/erk1/2, mek1/2, makp/jnk1/2, mapk/p38 as well as the serine/threonine protein kinase akt in lung adenocarcinoma cell lines, evaluated by immunoblotting using specific antibodies against phosphorylated erk, mek, jnk, p38, or akt. the results showed that high cellular levels of map4k4 appeared to coincide with high levels of phosphorylated erk1/2, but not phosphorylation of mek1/2, jnk, p38, or akt (fig. 3a), suggesting that erk is likely downstream signaling mediator of map4k4.",pmc5467491,1,100,40,1,140
117,map4k4,protein,,map4k4,uniprot,q9y4k4,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,i,activation,,a549,epithelial-like,lung,human,['1018'],nan,nan,"to further test that map4k4 bypasses mek to activate erk, we tested whether overexpression of map4k4 prevents mek inhibitor‐mediated inhibition of erk. the results showed that ectopic expression of map4k4 in a549 cells partially prevented mek inhibitor trametinib‐mediated inhibition of erk phosphorylation (fig. s4a), supporting that map4k4 activation could bypass the effect of mek inhibitor. consistent with this, we found that concurrent inhibition of map4k4 and mek with specific inhibitors exerted synergistic inhibitory effect on h23 cell proliferation (fig. s4b).",pmc5467491,1,100,40,1,140
118,map4k4,protein,,,uniprot,p57078,cytoplasm,go:0005737,erk,protein,,erk,uniprot,p27361,nucleus,go:0005634,positive,i,activation,,,lung adenocarcinoma,lung,mouse,['1021'],nan,nan,"we further conducted in vivo experiments to validate the functional importance of map4k4 in lung adenocarcinoma cells. in xenograft experiments, h1975 shrna control cells or map4k4‐knockdown cells were subcutaneously injected into the left or right flanks of the mice, respectively. as shown in fig. 5a, knockdown of map4k4 in h1975 cells caused significant reduction in tumor size. this result indicated that map4k4 is required for in vivo xenograft growth of h1975 cells. immunoblotting analysis of h1975 xenograft tumors revealed that erk activation was inhibited in map4k4‐knockdown cells (fig. 5b). in experimental metastasis study, h1975 shrna control cells or map4k4‐knockdown cells were injected into the tail vein of each mouse. results of this assay indicated that knockdown of map4k4 greatly impaired the ability of h1975 cells to metastasize to lung (fig. 5c–f). together, these findings provided first evidence that map4k4 regulates lung adenocarcinoma cell functions in vivo, presumably through inducing erk activation.",pmc5467491,1,100,40,1,140
179,ptprs,protein,,,uniprot,p23467,intracellular,go:0005622,erk,protein,,mapk1,uniprot,p28482,intracellular,go:0005622,positive,d,association,,"hct116, km12l4a",,,human,['317'],nan,nan,"in order to explore if ptprs associated with erk, we sought to determine if immunoprecipitates of ptprs contained erk. hct116 and km12l4a cells were grown and transfected with plasmid containing ptprs constructs with flag tag or with empty vector. cells were grown for 48 hours and then harvested for cell extract preparation. the ptprs was immunoprecipitated with antibody to the flag. the immunoprecipitates were analyzed by western blotting with antibodies to ptprs-flag and erk. figure 3c shows the ptprs immunoprecipitates contained erk and ptprs. conversely, when the extracts were immunoprecipitated with erk they were shown to contain ptprs by western blotting (fig. 3c). these data demonstrate that ptprs and erk were likely associated in these cells.",pmc6006154,1,100,40,1,140
178,ptprs,protein,,,uniprot,o14522,,,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,,,,,['309'],nan,nan,inhibition of ptprs with a peptide specific inhibitor activated erk and akt,pmc6006154,1,100,40,1,140
177,ptpn11,protein,non-receptor type,ptpn11,uniprot,q06124,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,activate,,,multiple,multiple,human,['330'],nan,nan,"receptor type and non-receptor type protein tyrosine phosphatases (ptps) are thought to be important in regulating the ras/erk pathway, although their functional role in cancer is much less understood than their counterpart protein tyrosine kinases (ptks)37–39. for example, receptor-type ptps ptpre (ptpε) and ptprj (dep-1) were shown to inhibit erk activation in vitro using nih3t3, hek293 and/or hela model cell lines40,41. recently, ptpn11 (shp2), a non-receptor type ptp, was reported to play an oncogene-like role in laryngeal cancer, hepatocellular carcinoma and glioblastoma, and the mechanism appeared to involve dephosphorylating ras to activate the ras/erk pathway42–44. moreover, while genetic and epigenetic alterations in a number of ptps have been observed in crc3,5,6,28,38,45,46, a role for these ptps in regulating ras/erk pathway is not yet known.",pmc6006154,1,100,40,1,140
176,ptpn1,protein,,ptpn1,uniprot,p18031,,,cjun,protein,,jun,uniprot,p05412,,,positive,d,phosphorylation,,293 t,epithelial-like,kidney,human,['284'],nan,nan,"293 t cells were transfected with pfa2-cjun, pfr-luc, and p3xflag cmv-ptpn1 (wt, ptpn1 d181a, or empty vector), and incubated for 24 h. after serum starvation (2 h), cells were treated with tnfα for the indicated time periods. samples were prepared for, and analyzed by luciferase assay (promega), according to the manufacturer’s instructions.",pmc5636874,1,100,40,1,140
174,ptpn1,protein,,ptpn1,uniprot,p18031,cytoplasm,go:0005737,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,negative,d,reduces phosphorylation,,,,,tnfα,['274'],nan,nan,"to elucidate the mechanism by which ptpn1 regulates the overall jnk signaling, we examined the level of phosphorylated jnk at regular intervals after treatment with tnfα (fig. 3d,e). when ptpn1 was expressed, jnk phosphorylation was reduced by approximately half compared to that achieved in the absence of ptpn1 expression. however, the timing of jnk activation or deactivation was not affected by ptpn1 expression.",pmc5636874,1,100,40,1,140
85,h-ras,protein,,hras,uniprot,p01112,,,stat3,protein,,stat3,uniprot,p40763,mitochondria,go:0005739,positive,d,phosphorylation,s727,,,,,['26'],nan,nan,"the data described above document that h-ras activation of mek-erk signaling results in phosphorylation of stat3 on s727, and that the expression of a mitochondrially-restricted phospho-mimetic stat3 supports ras transformation. however, these data do not address directly the requirement of mitochondrial s727 phosphorylation in ras-transformation. if stat3 s727 phosphorylation is a critical mek-erk target, then inhibition of this pathway in h-rasv12 transformed cells should impede colony formation. moreover, if this phosphorylation event is a major erk pathway target, then mts-stat3s727d mutation might be expected to support cell transformation even in the presence of mek-erk inhibition. to test this hypothesis, we performed colony assays on a panel of h-rasv12 transformed cells expressing wild-type stat3, no stat3, mts-stat3 or mts-stat3 s/d in the presence of increasing titrating concentrations of the mek inhibitor, pd0325901.",pmc3843736,1,100,40,1,140
86,h-ras,protein,,hras,uniprot,p01112,,,stat3,protein,,stat3,uniprot,p40763,mitochondria,go:0005739,positive,i,require,,,,,human,['29'],nan,nan,"activating mutations in h-ras occur in bladder, testicular and thyroid cancers, but are rare in other human cancers. the overall prevalence of h-ras mutation in cancer is small compared to k- and n-ras mutations [27]. mutant k- and n-ras are observed in approximately 20% of all human cancers, making them amongst the most prevalent activated proto-oncogenes. despite having 85% sequence identity, the distinct ras oncoproteins differ in both their level of expression and in a critical c-terminal hyper-variable region, which is subject to alternate farnesyl or palmitoyl lipidation controlling subcellular localization and signaling strength [28]. we previously showed that n-, k- and h-ras all require the mitochondrial activity of stat3 for transformation. because n-, k- and h-ras can all engage the raf-mek-erk pathway, it was of interest to test whether pathway activation was critical for mitochondrial stat3 s727 phosphorylation and transformation.",pmc3843736,1,100,40,1,140
87,h-ras,protein,,hras,uniprot,p01112,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,,stable cell lines,,,human,['11'],nan,nan,"to address this question, we employed h-ras mutants that selectively activate individual ras effector pathways [21,22]. activating mutations in ras (at codons 12, 13 or 61) lock it in a gtp bound (active) state, while a second mutation in the effector domain restricts ras signaling to a single downstream pathway (i.e., the 35s mutation restricts h-ras signaling to the raf-mek-erk pathway; and the 40c mutation signals through the pi3k pathway) [23,24]. we generated stable cell lines expressing mutant h-rasv12, h-rasv12/35s or h-rasv12/40c and confirmed that the h-ras mutations were activating the expected downstream kinase pathways. h-rasv12 activated both the raf-mek-erk pathway (as shown by the phosphorylation of erk) and the pi3k pathway (as shown by the phosphorylation of akt). h-rasv12/35s preferentially signaled through raf-mek-erk, inducing erk phosphorylation (figure 1a, lane 3), whereas h-rasv12/40c activated the pi3k-akt pathway, inducing akt phosphorylation but not erk phosphorylation (figure 1a, lane 4).",pmc3843736,1,100,40,1,140
186,ptprs,protein,,,uniprot,q9gzv5,,,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,reduces phosphorylation,,"hct116, km12l4a",colorectal cancer,,,['314'],nan,nan,"to support and validate the observations seen in fig. 2, we overexpressed ptprs in the two crc cell lines (hct116 with mutant kras and km12l4a with wild-type kras) with crispr knockout of ptprs to determine if the exogenous expression of ptprs could reduce the phosphorylation of erk. the exogenously expressed ptprs seen in fig. 3(a,b) did reduce erk phosphorylation that appeared independent of kras mutational activation. thus, the data (figs 2 and 3) indicate that ptprs negatively regulates erk phosphorylation.",pmc6006154,1,100,40,1,140
182,ptprs,protein,,,uniprot,q13332,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,de-phosphorylation,,"hct116, km12l4a",colorectal cancer,colonic,human,['327'],nan,nan,"effects of endogenous native ptprs mutations on erk de-phosphorylation assay. (a) endogenous, native mutations were selected for further study based on frequency and location. 7 plasmids containing selected point mutations were synthesized. additionally, 3 truncated mutants were synthesized. (b,c) hct116 (kras g13d/+) and km12l4a (wt kras) ptprs ko cells were transfected with the various mutant plasmids and cultured for 48 hours. extracts were prepared and levels of erk and akt phosphorylation were determined with western blotting. results show that 6 of 10 mutations we tested (r714c, r1608q, r1384q, -d2, -d1&d2 and –ig) exhibited completely or considerably reduced ptprs activity compared to wt ptprs plasmid. similar results were observed in both cell lines tested. the experiments were done in triplicates. quantitations were determined by normalizing the phosphorylated protein values with the total protein. all experiments were done in triplicate. the mean and standard deviation are shown. two-tailed, paired t test was used to determine the statistical significance for comparison between wt ptprs (ref) and ptprs mutants. significant p values (<0.05) are shown; * − near significant p values; vector − empty vector as a control.",pmc6006154,1,100,40,1,140
183,ptprs,protein,,,uniprot,q13332,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,s473,,,,human,['335'],nan,nan,"deletion of ptprs was reported to be associated with abnormal activation of pi3k/akt signaling in head and neck cancers25. we also found that ptprs inhibition/ko in crc cell lines, regardless of ras mutation status consistently increased akt phosphorylation at s473, indicating activation of akt (figs 2 and 4). there exists a crosstalk between ras signaling and pi3k/akt signaling47,51–53. however, whether increased phosphorylation of erk and akt by ptprs ko were inter-dependent is not known yet. mek has been suggested as a focal point for cross-cascade regulation51. however, inhibition/loss of ptprs increased p-erk and p-akt without moderating p-mek in most of cell lines tested. thus, mek likely did not play a role here.",pmc6006154,1,100,40,1,140
102,kras,gene,,kras,uniprot,p01116,,,erbb2,gene,,erbb2,uniprot,p04626,,,positive,i,activation,protein kinase domain,,,mucinous carcinoma,,['1208'],nan,nan,"among 26 mbot cases, 39 presumed somatic mutations were detected across seven genes: kras (24/26; 92.3 %), tp53 (3/26; 11.5 %), cdkn2a (5/26; 19.2 %), pik3ca (4/26; 15.4 %), pten (1/26; 3.8 %), gna11 (1/26; 3.8 %), and erbb2 (1/26; 3.8 %) (table 1 & fig. 2). amongst these mbots, kras mutations involved the “hotspot” for gly-12 only (additional file 1). when grouped based on kras hotspot mutant and erbb2 amplification status we observed 22 (84.6 %) kras+/erbb2-, one (3.8 %) kras-/erbb2+, two (7.7 %) kras+/erbb2+, and one (3.8 %) kras-/erbb2-; however, this last case harboured an erbb2 p.asp769asn mutation rather than amplification. despite the moderate frequency of amplification events, activating mutations of erbb2 have not previously been implicated in mucinous carcinoma pathogenesis. mutations to the 769 residue are expected to have an activating effect given they are within the protein kinase domain [31–33]. such mutations have been reported previously in both lung and esophageal cancers [34, 35].",pmc4494777,1,100,40,1,140
101,kras,gene,,kras,uniprot,p01116,cytoplasm,go:0005737,mek,protein,,,uniprot,p36507,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['176'],nan,nan,"in the assessment of the predictive ability for kras/braf mutation status, the affymetrix _ff 16-gene classifier produced the lowest misclassification rate (19 %) on the 54 samples. our pam analysis could further reduce the modified ras pathway signature gene set from 16 to 7 genes in the affy_ff classifier. whereas all 18 genes were selected for capacity to identify mek pathway activity independent of tumor genotype, the majority of the selected genes have particularly strong and direct relationships to the ras/mek/erk pathway activation. dusp4/6 [40] and phlda1 (tgad51) [41] are known transcriptional targets of mek/erk. etv4/5 [42] can replace ras/mapk pathway activation and trib2 can enhance erk phosphorylation [43]. these relationships point to the strength of the signature genes identified by the algorithms applied to our sample sets. of interest, serpinb1 was retained in affy_ff and nanos_ffpe sample sets but appeared to have no direct relationship to ras pathway activation.",pmc5069826,1,100,40,1,140
184,ptprs,protein,,,uniprot,q13332,,,erk,protein,,mapk1,uniprot,p28482,,,positive,d,phosphorylation,,"hct116, sw620, km12l4a",,,human,['311'],nan,nan,"western blot analysis for erk and mek activation. the indicated crc cell lines were cultured, cells harvested, extracts prepared and western blots performed. (a) cells (hct116, sw620 and km12l4a) cultured with isp, an inhibitor of ptprs, or a scrambled control peptide (sc). western blots to detect erk, tyrosine phosphorylated erk, mek and phosphorylated mek, and akt and phosphorylated akt are shown as indicated. the quantitations were determined by normalizing the phosphorylated protein values with the total protein; then dividing the isp values by the sc values. (b) the indicated cells had ptprs knocked down with sirna to ptprs (siptprs) or were treated with a scrambled sirna control (sictl). western blot analysis shows ptprs, phospho-erk, erk, phospho-mek, mek, phospho-akt, akt, and alpha-tubulin. knockdown of ptprs via sirna shows results consistent with the isp treatments. (c) crispr knockouts of ptprs in hct116, sw620, and km12l4a cell lines and their crispr control cell lines where cell extracts were used in western blot analysis for phosphorylation of erk and mek. this analysis shows ptprs, erk, phospho-erk, mek, phospho-mek, akt, phospho-akt, and alpha tubulin in the cell line pairs (ctl and ko) as indicated. (d) ddpcr analysis of ptprs expression in crispr ko cells for hct116, sw620, and km12l4a. analysis of the ddpcr result shows a near complete knockout for hct116 and km12l4a; sw620 shows >85% knockout. all experiments were done in triplicate. the mean and standard deviation are shown. two-tailed, paired t test was used to determine the statistical significance for comparison as indicated.",pmc6006154,1,100,40,1,140
185,ptprs,protein,,,uniprot,q16849,,,ras,protein,small gtpase,hras,uniprot,p01112,,,negative,d,reduction of active ras,,km12l4a and hct116,colon cancer,colon,human,['320'],nan,nan,"ptprs ko cell lines, km12l4a and the isogenic hct116 (−/+), show a reduced amount of active ras. km12l4a was also used for negative and positive controls incubating the samples with gdp and gtpσ; hct116 and hct116 (−/+) samples were incubated with gtpσ as a positive control.",pmc6006154,1,100,40,1,140
187,ptprs,protein,,ptprs,uniprot,o14522,plasma membrane,go:0005886,mek,protein,,mek,uniprot,p36507,cytoplasm,go:0005737,negative,d,inhibition,,hct116,epithelial,colon,human,['341'],nan,nan,hct116 ptprs ko and control cells were plated in 6-well plates. after 24 hours the cells were treated with 5 μm of mek inhibitors pd98509 (cat.no.p215 sigma). cells treated for 24 hours were then either harvested for western blot analysis or used for immunofluorescent staining.,pmc6006154,1,100,40,1,140
88,h-ras,protein,oncogene,hras,uniprot,p01112,plasma membrane,go:0005886,stat3,protein,transcription factor,stat3,uniprot,p40763,mitochondria,go:0005739,positive,d,transformation,soft agar,mefs,fibroblast,,mouse,['35'],nan,nan,"previous data have shown that strong constitutive activation of each of these pathways in isolation can transform mefs, but not as potently as activated h-ras. however, like the ras oncogenes themselves, activation of each individual pathway could not transform stat3-/- mefs [12]. as confirmed and expanded in this study, activation of the raf-mek-erk pathway in the absence of stat3 led to significantly fewer soft agar colonies compared to cells engineered to express mitochondrially restricted stat3 (figure 2a). moreover, cells expressing a mitochondrially restricted stat3 mutated to mimic phosphorylation at s727 (s727d) formed modestly but statistically significantly more colonies than those expressing wild type mitochondrial stat3. in contrast, limited cell transformation observed in the presence of activated pi3k was not increased by mitochondrial stat3, whether or not s727 phosphorylation was mimicked. these data demonstrate that the mitochondrial pool of stat3 can support transformation in cells with activated erk, but not pi3k.",pmc3843736,1,100,40,1,140
188,ptprs,protein,,ptprs,uniprot,p23470,cellular membrane,go: 0031224,phospho-erk,protein,phosphorylated,erk,uniprot,p27361,nucleus,go: 0005634,negative,i,expression,,hct116 and km12l4a,carcinoma,colon,human,['315'],nan,nan,"transfections of ptprs plasmid back into crispr ko cells decreases phospho-erk. hct116 and km12l4a crispr ptprs ko cells and their crispr control cells were grown and transfected with full length ptprs containing vector or empty vector alone. 48 hours after transfection cells were harvested and analyzed for erk, akt and mek phosphorylation. panel (a) western blots are for hct116 crispr ptprs (ko) knockout cells and crispr controls (ctl) as indicated. cells not treated (nt), transfected with empty vector alone, and transfected with plasmid with ptprs are shown. panel (b) is the same as panel (a) but with km12l4a cells. the ptprs expression is shown in two blots. the top blot is a darker exposure to elucidate the native ptprs expression in the control cells. the second blot for ptprs is a lighter exposure to show the ptprs expression of the plasmid transfected cells. quantitations were determined by normalizing the phosphorylated protein values with the total protein; then dividing the ptprs ko by the crispr control values. all experiments were done in triplicate. the mean and standard deviation are shown. two-tailed, paired t test was used to determine the statistical significance for comparison as indicated. (c) co-immunoprecipitation of flag-tagged ptprs and erk. flag-tagged ptprs was transfected into hct116 and km12l4a ptprs ko cells. cell lysates were then immunoprecipitated (ip) with a flag ab (left blots). the flag ip was successful in pulling down the flag-tagged ptprs as well as pulling down erk (lane 3 of left panel). conversely ptprs transfected cells were also immunoprecipitated using an erk ab (right panel). it was showed that the flag-tagged ptprs was pulled down along with erk (lane 3 of right panel), again supporting a direct association between ptprs and erk.",pmc6006154,1,100,40,1,140
94,jip1,protein,scaffold,,uniprot,o60610,cytoplasm,go:0005737,jnk,protein,kinase,mapk8,uniprot,p45983,cytoplasm,go:0005737,negative,d,dephosphorylation,tpy motif,,,,human,['278'],nan,nan,"the formation of protein complexes often mediated by scaffold proteins increases the proximity between signaling components, and thereby facilitates signal transduction7,8,49. scaffold protein-mediated mapk pathway signals are transmitted by relayed phosphorylation of member kinases3,4. malfunction of the signaling components or dysregulation of the signal transduction pathway have been previously investigated as putative therapeutic targets15. in this study, identification of a negative regulator of the jnk pathway was achieved via a facile synthetic screening approach using scaffold protein-tethered phosphatase fusion proteins (fig. 1b). this was possible because when jip1 interacts with jnk pathway kinases during the signal transduction process, a phosphatase expressed as a scaffold-fused protein is more accessible to kinases than a free form of phosphatase is. furthermore, the effect of each phosphatase increased as a result of close proximity to the jip1 signaling complex, and this augmented effect enabled the identification of ptpn1 as a novel negative jnk pathway regulator. ptpn1 was shown to catalyze jnk inactivation by dephosphorylating tyrosine residue in an active jnk (fig. 3c). the utilized anti-dual phospho-jnk antibody can capture phosphorylated jnk only when both the threonine and tyrosine residues of the tpy motif in the activation loop of jnk are phosphorylated to produce a fully activated form of jnk50. therefore, the decrease in the dual phospho-jnk and phospho-tyr blottings by ptpn1 (fig. 3c) suggests that ptpn1 may directly dephosphorylate the phosphotyrosine residue present in the tpy motif.",pmc5636874,1,100,40,1,140
189,ptprs,protein,,ptprs,uniprot,p23470,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,inactivation,nucleus,,colorectal cancer,colon,human,['304'],nan,nan,ptprs regulates colorectal cancer ras pathway activity by inactivating erk and preventing its nuclear translocation,pmc6006154,1,100,40,1,140
190,ptprs,protein,,ptprs,uniprot,q06418,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,activation,erk,,colorectal cancer,,human,['336'],nan,nan,"finally, it was important to assess the functional effects of a variety of the observed, native ptprs mutations. we sought to test the most commonly observed somatic alterations (fig. 7). surprisingly, when compared to wild-type ptprs, 4/7 tested native variants had a measurable deleterious effect on ptprs function as measured by erk activation (fig. 7). moreover, we were able to demonstrate a functional role for the ig-set domain and for the d1 + d2 domains via deletion constructs. these data suggest that a substantial percentage of the ~10% snvs observed in crc may have a deleterious functional effect.",pmc6006154,1,100,40,1,140
191,ptprs,protein,phosphatase,,uniprot,q13332,intracellular,go:0005622,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,modulation,,"hct116, km12l4a",colorectal cancer,colon,human,['324'],nan,nan,"the loss of ptprs brought about elevated erk signaling in crc cell lines as demonstrated by the increased protein expression of erk-regulated genes. since ptprs was reported to be an egfr phosphatase in other cancer cell lines25–27, we wanted to determine if the effect of ptprs ko might be through modulating egfr activity, upstream of ras signaling. we first examined the level of egfr phosphorylation at y1068 and y1173 in crc cell lines, with and without expressed ptprs (crispr ko). figure 6a shows that no change in p-egfr at y1068 and y1173 in hct116 parental cells, whereas sw620 lacked expression of both p-egfr and egfr. however, we observed that ptprs ko caused a modest, but statistically significant, increase in the egfr phosphorylation at y1068 and y1173 in hct116 (−/+) and km12l4a cells both of which have wt kras. to further confirm a role of kras mutation status in ptprs ko-mediated modulation of egfr phosphorylation response, we used isogenic cell pairs hct116 (kras g13d/+) vs hct116 (−/+) with and without ptprs expression. cells were starved for 24 hours and then challenged with egf. at the indicated times after egf addition, cells were harvested, and the amount of phosphorylated egfr was determined by western blotting. we found that in hct116 (kras g13d/+) cells, ptprs ko had no or minimal effect on egfr phosphorylation (fig. 6b,d). however, wild-type kras hct116 (−/+) cells lacking ptprs had a more prolonged activation of phospho-egfr than cells containing ptprs (fig. 6c,d). similar to p-egfr, a stronger effect on the akt phosphorylation was also seen in wild-type kras hct116 cells (fig. 6b–d).",pmc6006154,1,100,40,1,140
89,h-rasv12,protein,,hras,uniprot,p01111,plasma membrane,go:0005886,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,d,phosphorylation,,mefs,fibroblast-like,mouse liver,mouse,['12'],nan,nan,"(a) protein extracts from mefs transformed with h-rasv12 (v12) or h-rasv12 effector domain mutants (35s or 40c) were resolved by 10% sds-page, transferred to pvdf membranes and probed with phospho-specific antibodies against py705 stat3 (py stat3), ps727 stat3 (ps stat3), py204 erk (perk), ps473 akt (pakt), or total stat3, erk, akt and tubulin, as indicated. protein lysate from mouse liver 4 h following an injection with 30µg of lipopolysaccharide was used as a positive control (+ve). (b) h-rasv12 transformed mefs were treated with dmso (unt), rapamycin (10nm), ly294002 (50µm) or pd0325901 (1µm) for 2 h. cell lysates were processed for immunoblotting and probed with phospho-specific antibodies against ps727 stat3 (ps stat3), pt389 p70 s6 kinase, py204 erk (perk), ps473 akt (pakt), or total stat3 and tubulin as loading controls. (c) h-rasv12 transformed mefs were treated with the indicated dose of pd0325901 or vehicle (dmso) for 2 h. cell lysates were processed for immunoblotting and probed with phospho-specific antibodies against ps727 stat3 (ps stat3), py204 erk (perk), ps473 akt (pakt), or total stat3 and total erk as loading controls. (d) n-ras transformed human thp-1 acute myelocytic leukemia cells were treated with the indicated doses of pd0325901 (nm) or vehicle (dmso) for 2 h prior to the preparation of cell lysates for immunoblotting. lysates were probed for the indicated proteins and phospho-proteins as described in panel (c).",pmc3843736,1,100,40,1,140
173,ptpn1,protein,,ptpn1,uniprot,p18031,cytoplasm,go:0005737,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,negative,d,dephosphorylation,,,,,human,['267'],nan,nan,"44. with these studies, ptpn1 has become an attractive therapeutic target of diabetes and obesity. in the present study, ptpn1 was shown to reduce tnfα-stimulated cell death responses via direct dephosphorylation of jnk, and thus was identified as a novel negative regulator of jnk signaling pathway.",pmc5636874,1,100,40,1,140
141,nf1,gene,,nf1,hgnc,7776,,,ras,protein,,ras,uniprot,p01116,,,negative,d,gap activity,,,hematopoietic,,mouse,['763'],nan,nan,"the nf1 gene encodes neurofibromin (nf1), a gap that inhibits ras signaling by stimulating hydrolysis of active ras–gtp into inactive ras–gdp. inactivation of nf1 by gene microdeletion and mutation have been found at low frequency in both t and b lineage all (52, 53). in mouse models, somatic inactivation of nf1 in hematopoietic cells induces an mpd (54). chromosomal translocation events, including bcr/abl and those involving the mll locus, also cause constitutive activation of the ras pathway (55–57).",pmc4067595,1,100,40,1,140
180,ptprs,protein,,,uniprot,p23470,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,nucleus,go:0005634,positive,d,affects localization,,hct116,,colon,human,['329'],nan,nan,"ptprs affects the localization of erk. (a) immunofluorescent staining shows erk nuclear localization in hct116 ptprs ko cells (upper left) and general whole cell staining in hct116 control cells (lower left). a comparison of the control cells to the ko shows that the ptprs ko cells have nuclei that are enriched with total erk (arrow in top left compared to arrow in bottom left). the erk phosphorylation in its location is confirmed with a mek inhibitor (pd98509, middle panels). the inhibition of mek prevent erk phosphorylation resulting in erk not being translocated to the nucleus (middle images have nuclei with very low-stained signals for erk). staining for phospho-erk (right panels) shows a very dynamic difference with the ptprs ko cells showing a bright signal and the control cells having very weak signal. supplementary fig. 4 shows the linear profile of fluorescence intensity for both dapi and erk/phospho-erk. these measurements confirm the increased signal seen in the nuclei of ptprs ko cells. (b) western blot for the cells in fig. 8a. the left two lanes are untreated hct116 cells and right two are treated with 5 μm of mek inhibitor pd98509 for 24 hours. the upper blot confirms the ptprs knockout in the ko cells. the lower blots for phospho-erk and total erk confirm the increased phospho-erk for the ptprs ko in the left two lanes. the right most lanes confirm that the meki prevented the phosphorylation of erk. (c) multichannel blot of cells transfected with ptprs with a c-terminal flag tag. this blot uses both a ptprs (rabbit green) and flag (mouse red) antibody. here the cleavage of ptprs is illustrated. full length ptprs is 217 kda (yellow), the n-terminal subunit containing extracellular and transmembrane domains are 140 kda (green) the c-terminal subunit containing phosphatase d1 and d2 domains are 78 kda (red). this cleavage was a consistent result, and seen in all cell lines used. (d) assessment of ptprs transfection on erk localization. hct116 and km12l4a ptprs ko cells were transfected with a rfp c-terminal tagged ptprs. here we examined the localization of ptprs (red) and total erk (green) as well as their co-localization (orange). the ptprs transfected cells (red) show a critically reduced level of erk in their nuclei (white arrows) when compared to the cells not over expressing ptprs (red arrows), which have bright green nuclei (erk). (e) western blotting corresponding to the cells used in 8d and 8f. the left three lanes show the ptprs ko compared to the control cells and ptprs ko cells transfected with ptprs. the third lane shows that ptprs transfected back into ptprs ko cells reduces the increased phospho-erk back to levels equivalent to the control cell line. the right three lanes show the isp inhibited the transfected ptprs activity allowing for increased phospho-erk. (f) the nuclear reduction of erk as a result of ptprs transfection is reversed when ptprs is inhibited by the isp. hct116 and km12l4a ptprs ko cells were transfected with the rfp tagged ptprs and then treated with the ptprs inhibitor isp. the reduction in nuclear erk (8d) is completely reversed (8f) when ptprs is inhibited. both the cells overexpressing ptprs (white arrows) and non-transfected cells (red arrows) show bright erk signal in their nuclei. supplementary fig. 5 shows the dapi stains for these images. (g) duo-link in situ staining for ptprs and erk co-localization. hct116 ptprs ko cells were transfected with a c-terminal flag tagged ptprs or control empty vector. the cells were then labeled with a flag mouse ab and an erk rabbit ab. the red dots indicate a successful duolink reaction, which requires both antibodies to be in close proximity. the ptprs transfected cells show an ample amount of red signal (left), and the empty vector cells do not show a significant amount of signal (right). these data suggest a direct association between ptprs and erk.",pmc6006154,1,100,40,1,140
142,nf1+/−,protein,mutant,nf1,uniprot,p21359,striatum,go:0005740,ras,protein,gtp,ras,uniprot,p01116,striatum,go:0005740,positive,d,activation,striatum,,,striatum,mouse,['1221'],nan,nan,nf1+/− mutant mice show high striatal ras-gtp levels but reduced camp levels,pmc6194127,1,100,40,1,140
34,crebbp,protein,,crebbp,uniprot,q92793,nucleus,go:0005634,kras,protein,gtpase,kras,uniprot,p01116,cytoplasm,go:0005737,positive,d,acetylation,,,,,human,['187'],nan,nan,"in vitro acetylation assays were performed to detect acetylation of kras by crebbp using recombinant crebbp and kras proteins (both sigma-aldrich, vienna, austria). reaction was carried out for 1 hour at 30°c in non-denaturing lysis buffer with the addition of 10 μm sodium butyrate and 25 μm acetyl-coa. enzymatic reaction was terminated by addition of 6×sds loading buffer and heating at 90°c for 10 minutes. acetylation levels were assessed by western blot analysis.",pmc5395114,1,100,40,1,140
231,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,mapks,protein,,mapk,uniprot,p28482,cytoplasm,go:0005737,negative,d,regulate,astrocyte activation,,,brain,,['941'],nan,nan,interactions between sirt1 and mapks regulate astrocyte activation induced by brain injury in vitro and in vivo,pmc5372348,1,100,40,1,140
32,crebbp,protein,,crebbp,uniprot,q92793,,,kras,protein,,kras,uniprot,p01116,,,positive,d,acetylation,,,b-cell,,human,['195'],nan,nan,"recent studies have shown that crebbp mutations frequently co-occur with ras mutations in childhood hhd all.18,24 to test for acetylation of kras by crebbp, we performed in vitro acetylation assays using recombinant proteins. direct acetylation of kras was shown in the presence of crebbp, identifying kras as a substrate for crebbp (figure 7a). the functional impact of crebbp attenuation on ras pathway signaling was investigated by rnai-mediated knockdown of crebbp in preb 697 cells which harbor nras (g12d) mutation and in 3 ras pathway mutant hhd all primagrafts (l779, l829r and l914) with nras (q61r), kras (g13d) and cbl/flt3 (δ836) mutations (online supplementary table s1). western blotting showed an increase in p-erk levels in preb 697 shcbp cells compared to shneg cells and in l829r and l914 primagraft all samples after sicbp knockdown, suggesting that crebbp reduction enhances ras pathway activation (figure 7b and c). to assess the influence on sensitivity to mek inhibition (meki), preb shcbp and shneg cells were dosed with the benchmark meki, u0126. crebbp knockdown had no effect on sensitivity to u0126 (gi50 values, mean±sd; shcbp 9.8 μm±3.5 vs. shneg 10.4 μm±sd 1.7; p=0.8) (figure 7d). crebbp knockdown in mhh-call-2 cells, which lack ras pathway mutations, did not alter p-erk levels or meki sensitivity (online supplementary figure s2).",pmc5395114,1,100,40,1,140
232,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,p38mapk,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,positive,d,activation,,,,brain,,['979'],nan,nan,"the possible interactions between sirt1 and erk, jnk, or p38mapk pathway in traumatic brain injury. the brain injury reduced endogenous sirt1 level and activated erk, jnk, and p38mapk pathways. overexpressed sirt1 attenuated astrocyte activation and decreased erk, jnk, and p38mapk activation. inhibition of erk, jnk, or p38mapk activation increased sirt1 expression and attenuated astrocyte activation",pmc5372348,1,100,40,1,140
233,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,p38mapk,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,positive,d,interacted,erk pathway,,astrocyte,brain,human,['980'],nan,nan,"in summary, this study found that sirt1 is an important topic for astrocyte activation induced by il-1β stimulation in vitro and traumatic brain injury in vivo; inhibition of erk, jnk, or p38mapk activation suppressed gfap upregulation and improved the cell hypertrophy to attenuate the astrocyte activation; sirt1 interacted with erk pathway activation via a synergic way, but an antergic way with jnk and p38mapk pathway activation to mediate the expression of gfap and astrocyte morphology that is the astrocyte activation. investigation of the regulation and levels of these and other signaling molecules may be a novel and effective strategy for neuroprotection after brain injury.",pmc5372348,1,100,40,1,140
234,son of sevenless (sos),protein,gef,,uniprot,q07889,cytoplasm,go:0005737,erk,protein,kinase,,uniprot,p27361,cytoplasm,go:0005737,positive,d,regulation,erk phosphorylation,lung scc cells,epithelial,lung,human,['105'],nan,nan,"the current study highlights the therapeutic efficacy of belinostat in lung scc cells and characterizes the downstream molecular signaling in belinostat‐treated cells. we have previously identified activation of mapk/erk as a mechanism of resistance to cisplatin (kong et al., 2015). the increase in erk phosphorylation upon cisplatin treatment was shown to be regulated by son of sevenless (sos) upstream. the current study demonstrates the promising chemosensitizing characteristic of belinostat in lung scc through the suppression of mapk activity. we further studied the mechanistic actions of hdac inhibition by analyzing the global gene expression profiling, and identified the possible role of ubiquitin‐proteasome pathway in the regulation of sos/mapk signaling.",pmc5537703,1,100,40,1,140
170,ptpn1,protein,,,uniprot,p18031,cytoplasm,go:0005737,jnk,protein,,mapk8,uniprot,p45983,nucleus,go:0005634,negative,d,regulation,,293t,fibroblast-like,,mouse,['276'],nan,nan,"ptpn1 regulates jnk-related cell death response. (a) flag-ptpn1 or flag-ptpn1 d181a was expressed in 293 t cells. control cells were transfected with an empty vector. upon tnfα-stimulation, protein expression and jnk phosphorylation were each examined by immunoblotting. (b) jnk activity was assessed using a luciferase reporter gene assay. the data are presented as the mean ± sd (repeats were performed in triplicate). (**p < 0.005) (c) flag-ptpn1 or flang-ptpn1 d181a was expressed in p65-deficient mef cells. after tnfα-stimulation (7 h), dead cells were visualized with pi staining (7 µg/ml) and observed via microscopy. (d) the relative cell death ratio was plotted ( ± sd, n = 3). (*p < 0.05).",pmc5636874,1,100,40,1,140
169,ptpn1,protein,,,uniprot,p18031,cytoplasm,go:0005737,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,negative,d,bind,,,mef,,human,['280'],nan,nan,"we also showed the catalytic mutant ptpn1 d181a could bind to jnk as efficiently as wt ptpn1 did. ptpn1 d181a failed to inhibit tnfα-stimulated jnk phosphorylation, and led to an increased cell death in p65-deficient mef cells (fig. 4). these results indicated that the negative regulation of tnfα-dependent jnk signaling by ptpn1 depends on its catalytic activity. thus, elucidation of the functional mechanism of ptpn1 may help to understand the jnk-dependent cell death, which is a prominent feature in several diseases, such as cancer, diabetes, inflammatory diseases, and neurodegenerative diseases14,16.",pmc5636874,1,100,40,1,140
147,nras,protein,,nras,uniprot,p01111,,,kras,protein,,kras,uniprot,p01112,,,positive,d,activating mutations,,,b-cell,,,['611'],nan,nan,"most recurrent lesions were activating mutations in nras and kras (79%), followed by mutations in ptpn11 and flt3 (9.3% and 10.1%, respectively; figure 1a and supplementary figure s3). mutations in braf, nf1, cbl and other genes occurred sporadically. overall, variants in ras pathway genes were observed in 44.2% of pediatric bcp-all cases. clonal mutations (vaf⩾25%) were found in 24.1% of all patients (median: 40.5% vaf; supplementary figure s4) and subclonal mutations (vaf<25%) were exclusively found in 20.1% of patients (median: 4.3% vaf).",pmc5886052,1,100,40,1,140
241,tcf7l2,protein,,tcf7l2,uniprot,q9nqb0,nucleus,go:0005634,perk/mek,protein,,mapk,uniprot,p27361,cytoplasm,go:0005737,negative,d,knockdown,anchorage-independent growth,,,,human,['1047'],nan,nan,"effects of stable shrna knockdown of foxo3, ncoa3, and tcf7l2 on anchorage-independent growth and perk/mek levels",pmc5755028,1,100,40,1,140
243,tgf-β,other,,,uniprot,p01137,extracellular,go:0031012,ras,protein,small gtpase,hras,uniprot,p01112,plasma membrane,go:0005886,positive,i,activation,ras,,,,human,['803'],nan,nan,"besides canonical smad signaling, tgf-β induces non-canonical, non-smad signaling including the ras—erk pathway, traf6—tak1—jnk/p38 mapk, rhoa/cdc42, and pi3k—akt signaling [15–17]. combination or crosstalk of these non-smad signaling pathways or between smad and non-smad signaling produces diverse biological responses of tgf-β, such as cell proliferation, differentiation, growth arrest, apoptosis, and emt. the ras-induced erk pathway (raf—mek—erk) is typically activated by growth factors through their receptor tyrosine kinases (rtks), which mobilize adaptor proteins, such as shc and grb2, and guanine nucleotide exchange factors (gefs) like sos. the rtk-mediated activation of a specific gef activates the small gtpase ras (h-, k-, and n-ras) via gtp loading. association of the activated ras with raf family proteins (b- and c-raf) leads to mek and erk activation through sequential phosphorylation [18–20]. similarly to rtks, activated tβris recruit and directly phosphorylate shca on tyr as well as ser [21]. although the tyr kinase activity of tβris is much lower than that of rtks, this phosphorylation of shca triggers association with grb2 and sos, thereby activating the ras—erk pathway.",pmc4440819,1,100,40,1,140
148,nrasq61r,protein,,nras,uniprot,p01111,,,brafv600e,protein,,braf,uniprot,p15056,,,positive,d,phosphorylation,,melanoma cells,,"soft agar, liquid medium, nude mice",,['1284'],nan,nan,"when compared to nrasq61r clones, melanoma cells bearing the brafv600e mutation have increased growth rate in soft agar, but lower proliferative ability in liquid medium and after grafting into nude mice [116]. notably, while the presence of braf/nras mutations in primary tumors do not negatively impact progression free or overall survival, for metastatic lesions, the presence of braf/nras mutations is associated with a shortened survival [119].",pmc6472057,1,100,40,1,140
167,pparγ,protein,,,uniprot,p37231,nucleus,go:0005634,p38 mapk,protein,kinase,mapk14,uniprot,q16539,cytoplasm,go:0005737,negative,i,inhibition,,,esophageal cancer cells,esophagus,human,['1398'],nan,nan,"in conclusion, our study demonstrated that pparγ activation inhibited proliferation and induced apoptosis esophageal cancer cells in vitro. pparγ activation also inactivated the tlr4 and erk, jnk, and p38 mapk pathways in esophageal cancer cells. this research highlighted that erk, jnk, and p38 mapk activation was regulated by tlr4 pathway, and that inhibition of tlr4, myd88, erk, jnk, and p38 attenuated proliferation and induced apoptosis esophageal cancer cells in vitro. therefore, the better understanding of the mechanisms by which pparγ functions as a suppressor in esophageal cancer is beneficial to pparγ agonist utilization for the treatment of esophageal cancer.",pmc5190119,1,100,40,1,140
248,tlr4,protein,,tlr4,uniprot,o00206,cell membrane,go:0016020,mapk,protein,,mapk,uniprot,p28482,cytoplasm,go:0005737,negative,d,inactivation,,esophageal cancer cells,,esophagus,human,['1393'],nan,nan,inactivation of tlr4 and mapk pathways suppresses proliferation and induces apoptosis of esophageal cancer cells,pmc5190119,1,100,40,1,140
250,trametinib,compound,,,pubchem,11707110,cytoplasm,go:0005737,p-erk1/2,protein,,,uniprot,p27361,cytoplasm,go:0005737,negative,d,inhibition,,paca,pancreatic cancer,,human,['1070'],nan,nan,"in contrast to rko results, we observed minimal potency shifts for trametinib in other ras pathway mutant cell lines sensitive to the bet/mek combination, such as the paca cell line hpaf-ii (supplemental figure s17), and co-treatment with gsk525762 did not further reduce p-erk1/2 compared to trametinib treatment in these cells. thus, reversal of adaptive resistance to mek inhibition likely contributes to the synergy observed for bet/mek combinations in a subset of ras pathway mutant models (ex: rko), but it is not the primary mechanism in all cell lines.",pmc5908790,1,100,40,1,140
35,crebbp,protein,,crebbp,uniprot,q92793,nucleus,go:0005634,kras,protein,,kras,uniprot,p01116,plasma membrane,go:0005886,negative,d,acetylation,switch ii domain,,b-cell,,human,['197'],nan,nan,"prompted by the observation that crebbp mutations frequently co-occur with ras pathway activating mutations, including kras, nras, ptpn11 and flt3,18 we investigated the influence of crebbp knockdown on ras signaling. both cell lines and primagraft all cells, with different ras pathway mutations, showed increased levels of p-erk after crebbp knockdown, suggesting that crebbp attenuation enhances ras signaling. we show that kras is directly acetylated by crebbp, a secondary modification shown to have a negative regulatory effect on ras activity by altering conformational stability of the switch ii domain and thus interaction with guanine nucleotide exchange factors.37 the link we have identified between mutations in epigenetic modifiers such as crebbp and enhanced oncogenic signaling is supported by a recent study in early thymocyte precursor all which found that inactivation of the methyltransferase, ezh2, co-operates with mutant ras to induce hyperactive cytokine signaling, principally through stat3, and was associated with a reduced sensitivity to jak inhibitors.38 further to this, inactivation of another methyltransferase, suz12, has also been shown to co-operate with ras signaling in a number of solid tumors, acting here to enhance downstream oncogenic ras transcriptional signatures.39 here, we show that, despite an enhanced ras pathway activation in crebbp attenuated all cells, sensitivity to meki was retained, which may have important clinical implications. our group has recently reported on the preclinical evaluation of the meki, selumetinib, and demonstrated significant differential sensitivity in ras pathway-mutated all compared to all without ras mutations, both in vitro and in an orthotopic xenograft model engrafted with primary all cells.23,40 clinical trials of selumetinib for relapsed ras pathway mutated all cases are underway, and the data presented here suggest that patients with co-occurring crebbp and ras mutations might still be good candidates for meki therapy.",pmc5395114,1,100,40,1,140
36,crebbp,protein,,crebbp,uniprot,q92793,nucleus,go:0005634,kras,protein,,kras,uniprot,p01116,plasma membrane,go:0005886,positive,d,acetylation,,"preb 697, l779, l829r, l914",b-cell,,human,['196'],nan,nan,"crebbp acetylates kras and attenuation of crebbp increased ras pathway signaling without altering sensitivity to mek inhibitors. (a) western blot showing the acetylation of the recombinant kras by crebbp as well as the autoacetylation of crebbp, using acetylated lysine antibody (top) and kras antibody (bottom) to confirm equal loading. (b) western blot for p-erk, erk and α-tubulin in crebbp knockdown preb 697 (shcbp and shneg), l779, l829r and l914 cells. (c) histogram of the relative expression of p-erk in preb 697 (shcbp and shneg) and crebbp knockdown primagraft samples normalized to erk and α-tubulin after densitometric analyses. (d) viability curves of preb 697 shcbp and shneg cells after 96-hour dosing with u0126. values plotted represent the mean±sd of 3 independent experiments.",pmc5395114,1,100,40,1,140
37,crebbp,protein,,crebbp,uniprot,q92793,nucleus,go:0005634,kras,protein,,kras,uniprot,p01116,plasma membrane,go:0005886,positive,d,substrate,,,,,,['194'],nan,nan,kras is a substrate of crebbp and knockdown of crebbp is associated with increased ras signaling,pmc5395114,1,100,40,1,140
225,siah,protein,,siah1,uniprot,q96ru3,,,egfr,protein,,egfr,uniprot,p00533,,,positive,i,expression,,,breast,cancer,human,['1373'],nan,nan,low or high siah and/or egfr expression post-nst is associated with increased or reduced patient survival in breast cancer at 5 years,pmc5049993,1,100,40,1,140
143,nm23-h1,protein,,nme1,uniprot,p15531,,go:0005576,rac1,protein,small gtpase,rac1,uniprot,p63000,,go:0005576,negative,d,inhibits,unknown,,unknown,unknown,human,['41'],nan,nan,"nm23-h1, also known as nme1, was the first identified metastasis suppressor gene [1]. the reverse correlation between nm23 expression and metastatic potential had been reported many times using cell lines and xenograft models (reviewed in [2]). the metastasis inhibitor effect was also demonstrated using mouse models: double transgenic mice derived from a cross of nm23-m1 knockout mice with a mouse strain prone to hepatocellular carcinoma show a higher incidence of lung metastases [3]. members of the nme gene family encode nucleoside diphosphate kinases (ndpk) [4]. in recent years ndpks have been ascribed numerous roles in development that are inconsistent with a simple housekeeping role of balancing pools of nucleoside diphosphates and triphosphates. recent data suggest that members of the nm23 family display multiple functions in diverse biological processes such as signal transduction, growth control, differentiation, cell migration, cancer promotion [5-7]. although the exact molecular process by which nm23 inhibits the metastatic potential of cancer cells is unknown, some molecular mechanisms have been proposed to explain its anti-metastatic activity. nm23 silencing in hepatoma and colon carcinoma cell lines resulted in upregulation of the membrane associated matrix metalloproteinase (mt1-mmp), increased rac1 signaling and activation of several pro-invasive signaling pathways such as mapk (mitogen activated protein kinase)/sapk (stress-activated protein kinases), akt [8]. elevated rac1 level upon nm23 knockdown suggests that nm23 inhibits rac1 activation. although the exact mechanism is unknown, nm23-h1 was shown to interact with factors involved in rac1 activation, such as the small gtpase arf6 or the nucleotide exchange factor tiam1 [9,10]. arf6 by recruiting nm23-h1 was reported to facilitate dynamin-mediated endocytosis during adherens junctions disassembly and nm23-h1 was suggested to provide a source of gtp for arf6 [9]. the highly specific functional relationship between dynamin and the nm23 homolog awd in endocytosis was demonstrated by genetic studies in drosophila[11]. awd functions as a negative regulator of cell migration in tracheal and border cells by downregulating receptor levels on the cell surface through dynamin-mediated endocytosis [12,13], thus it suppresses cell motility through receptor internalization. some studies suggest that nm23-h1/h2 may exert its anti-metastatic effect by blocking ras/erk (extracellular signal-regulated kinase) signaling [14-17]. in this review i summarize how nm23-h1 inhibits the ras/erk cascade in human cell lines, and examine how the nm23 homolog ndk-1 modifies the outcome of ras signaling in the model organism caenorhabditis elegans[18].",pmc4020307,1,100,40,1,140
220,ret,protein,receptor tyrosine kinase,ret,uniprot,p07949,plasma membrane,go:0005886,braf,protein,kinase,braf,uniprot,p15056,cytoplasm,go:0005737,positive,d,activating-point mutation,codon 600,,thyroid,,human,['203'],nan,nan,"rearrangements of the gene encoding the receptor tyrosine kinase ret and activating-point mutations of ras or braf are found in 70% of all cases of ptc and are mutually exclusive. mutation of braf, especially a valine to glutamic acid substitution at codon 600 (v600e) termed the brafv600e mutation, is the most frequent genetic alteration, identified in 60% of cases (range: 27%-87%) [1, 2]. ptcs with different mutations are recognized to have distinct histopathologic appearance and biologic properties. most studies in ptcs suggest that braf activating mutation is closely associated with extrathyroidal extension, lymph node metastasis, advanced tumor stages, disease recurrence, and even patient mortality [2]. the molecular mechanisms underlying the association of braf mutation with worse prognosis compared to ptc with no or other genetic alterations has so far only been partially elucidated. there is evidence that the transcriptional output of the mapk pathway is greatest in brafv600e mutant tumors, because this oncoprotein signals as a monomer and is therefore unresponsive to feedback inhibition on raf dimers [3].",pmc5599027,1,100,40,1,140
171,ptpn1,protein,,,uniprot,p18031,,,jnk,protein,,jnk,uniprot,p45983,,,negative,d,binds,,293 t cells,epithelial-like,,human,['275'],nan,nan,"when 293 t cells were treated with tnfα, those expressing ptpn1 were shown to exhibit reduced levels of jnk phosphorylation (fig. 3). to further evaluate the function of ptpn1, experiments using a catalytic ptpn1 mutant (ptpn1 d181a) were performed. data showed that ptpn1 d181a bound to jnk as efficiently as wild-type (wt) ptpn1 did, but exhibited reduced catalytic activity against jnk (figs s4 and s5). resultantly, although the binding affinity of ptpn1 d181a for jnk was similar to that of wt ptpn1, its expression did not reduce the level of jnk phosphorylation as wt ptpn1 did (fig. 4a). this observation was also confirmed by a luciferase reporter gene assay to monitor jnk catalytic activity (fig. 4b). together, wt ptpn1 decreased both jnk phosphorylation and luciferase activity, while ptpn1 d181a increased luciferase activity via prolonged jnk phosphorylation (fig. 4a,b). these results suggest that ptpn1 promotes jnk pathway inactivation.",pmc5636874,1,100,40,1,140
222,rxrα,protein,,rxra,uniprot,p19793,nucleus,go:0005634,cleaved caspase-3,protein,,casp3,uniprot,p42574,cytoplasm,go:0005737,positive,d,induction,,ec109 and te10 cells,esophageal cancer cells,esophagus,human,['1382'],nan,nan,"to study the role of pparγ activation in apoptosis of esophageal cancer cells, ec109 and te10 cells were treated with 20 μm of pparγ agonist rgz for 48 h, and apoptosis rate was measured using flow cytometric analysis. as shown in figures 2a, 2b, 2d and 2e, rgz induced apoptosis, reduced bcl-2 expression level, and elevated bax and cleaved caspase-3 expression levels in ec109 and te10 cells. furthermore, sirna-mediated knockdown of pparγ and rxrα in ec109 cells impaired the ability of rgz to induce apoptosis, reduced bcl-2 expression level, and elevated bax and cleaved caspase-3 expression levels (figure 1c and 1f). these data suggest that pparγ acts as a heterodimer with rxrα to induce apoptosis of esophageal cancer cells.",pmc5190119,1,100,40,1,140
223,siah,protein,,siah1,uniprot,o15145,cytoplasm,go:0005737,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0005886,negative,d,reduction,,,mammary,,human,['1366'],nan,nan,"among patients with ln metastases, the therapy-induced reduction in siah expression seemed to correlate with increased survival; i.e., the patients with low siah expression in both pre- and post-nst settings have the best prognosis and the greatest survival benefit despite their invasion phenotypes, whereas patients with high siah expression in both pre- and post-nst settings have the worst prognosis, suggesting that either ineffective therapy was administered or therapy-induced resistant tumor clones were emerging (figs. 3a, c–f, 4a, b and c). the patients with high siah expression at diagnosis and low siah expression post-nst have intermediate survival, suggesting that an effective nst modality was administered to inhibit tumorigenesis (figs. 3a, 4a, b and c). among patients with ln metastases, the therapy-induced reduction in egfr expression is statistically significant to correlate with increased survival (figs. 3b, c–f, 4d, e and f). patients with low egfr expression in both pre- and post-nst settings have the best prognosis despite their invasive phenotypes and ln positivity, whereas patients with high egfr expression in both pre- and post-nst settings have the worst prognosis, and patients with high egfr expression at diagnosis and low egfr expression post-nst have intermediate survival (figs. 3b, 4d, e and f). in the cases of persistent high egfr expression post-nst, additional anti-egfr therapy should be added to control these therapy-refractory and egfr-positive mammary tumors that have metastasized.",pmc5049993,1,100,40,1,140
224,siah,protein,,siah1,uniprot,q8iuq4,cytoplasm,go:0005737,k-ras,protein,,kras,uniprot,p01116,plasma membrane,go:0005886,positive,i,signal transduction,,,cancer,breast,human,['1370'],nan,nan,"as a major tumor-promoting pathway, ras pathway activation/inactivation is ideally positioned to serve as a therapy-responsive, tumor heterogeneity-independent, and growth-dependent prognostic biomarker in breast cancer. here, we conducted a retrospective study to determine whether the ras pathway biomarkers can be added to evaluate tumor response and therapy efficacy, forecast patient survival, and predict which patients with invasive breast cancer are likely to benefit from standard nst regimens, or which patients will benefit from additional regimens after ineffective first-line therapies are identified. siah function is required for proper her2/egfr/k-ras signal transduction, cancer cell proliferation and survival (schmidt et al., 2007, ahmed et al., 2008, qin et al., 2015, tang et al., 1997, adam et al., 2015). siah is expressed in proliferating tumor cells. we have previously associated increased siah expression with the progression of ductal carcinoma in situ (dcis) to invasive carcinoma (behling et al., 2010). we showed that combining five molecular biomarkers (egfr, siah, phospho-erk, ki67 and hif1α) in the oncogenic k-ras/ki67/hif1α pathways, with four clinicopathological predictors can be used to predict patient survival post surgery in human pancreatic cancer (qin et al., 2015). other groups have shown that siah expressed in breast cancer (wright et al., 2015, palmieri et al., 2009, bruzzoni-giovanelli et al., 2010, confalonieri et al., 2009, chan et al., 2011). importantly, we were the first group to demonstrate the efficacy of an anti-siah-based anti-k-ras and anticancer strategy to shutdown the “undruggable” oncogenic k-ras activation and successfully block oncogenic k-ras-driven tumorigenesis in several animal models of human cancer (schmidt et al., 2007, ahmed et al., 2008, van sciver et al., 2016, wong and moller, 2013).",pmc5049993,1,100,40,1,140
47,dusp6,protein,,dusp6,uniprot,q16828,,,erk,protein,,mapk1,uniprot,p28482,,,positive,i,phosphorylation,two different serines,,,,,['234'],nan,nan,"immunohistochemistry-based technique detection demonstrated that dusp6 levels are increased in ptcs in comparison with benign thyroid neoplasms. nevertheless, those levels were not correlated with brafv600e mutation status [31]. the complex transcriptional, post-transcriptional and post-translational regulation of dusp5 and dusp6 may explain that reproducible correlation between mapk pathway activation and dusps protein levels is hard to predict. in fact, accumulation of dusp5 and dusp6 protein upon erk activation [6, 7, 37–40] is regulated by rapid proteasomal degradation [6, 7, 11, 40]. moreover, erk can phosphorylate dusp6 on two different serines and subsequently enhances its proteasomal degradation [11]. as a consequence discrepancies between dusp6 protein and mrna levels have been frequently observed [6, 7, 39], which make the system even more complex to analyze.",pmc5599027,1,100,40,1,140
229,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,d,activation,,,brain,,human,['976'],nan,nan,"moreover, zhao et al. (2012) showed that sirt1 downregulation induced by the pharmacological inhibitor salermide or rna interference could attenuate the activation of erk after brain injury. in addition, the inhibition of erk activation could also decrease the sirt1 expression, suggesting that there may be some interactions between sirt1 and mapk cascade activation.",pmc5372348,1,100,40,1,140
46,dusp6,protein,erk specific phosphatase,dusp6,uniprot,q16828,cytoplasm,go:0005737,braf,protein,mutated,braf,uniprot,p15056,cytoplasm,go:0005737,positive,d,markers,erk specific phosphatases,,thyroid cancer,,human,['198'],nan,nan,"dusp5 and dusp6, two erk specific phosphatases, are markers of a higher mapk signaling activation in  braf  mutated thyroid cancers",pmc5599027,1,100,40,1,140
45,dorothy g. hoefer foundation for breast cancer research,foundation,,siah1,,o15146,,,a.h. tang,protein,,,,p00533,,,positive,i,supported by,,,,,human,['1352'],nan,nan,"this work was supported by the dorothy g. hoefer foundation for breast cancer research (a.h. tang); center for innovative technology (cit)-commonwealth research commercialization fund (crcf) (mf14s-009-ls to a.h. tang), and national cancer institute (ca140550 to a.h. tang).",pmc5049993,1,100,40,1,140
44,dna topi,protein,,top1,uniprot,p11387,nucleus,go:0005634,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,inhibition,,"snu-1, hgc27, nci-n87",,,human,['784'],nan,nan,"to investigate molecular events underlying gimatecan treatment, expressions of dna topi and molecules involved in akt and mapk pathways were quantified with western blot. gimatecan treatment significantly inhibited expression of dna topi in snu-1 (fig. 3a), hgc27 (additional file 3: figure s3a) and nci-n87 (fig. 3b) cell lines at 100 nm or more, but irinotecan had little effect even at high concentrations. moreover, gimatecan significantly inhibited the akt pathway and activated the jnk2 and p38 mapk pathway, as indicated by inhibition of pakt, pmek, and perk, and upregulation of phosphorylated p38 mapk (p-p38) and phosphorylated jnk2 (pjnk2), respectively, in snu-1 (fig. 3a) and hgc27 (additional file 3: figure s3b) cells. however, in nci-n87 cells, gimatecan treatment only inhibited expression of pakt and perk (fig. 3b). our results indicated that snu-1 and hgc27 cells were more sensitive to gimatecan than nci-n87 cells, which was consistent with the result of cell viability.",pmc5729429,1,100,40,1,140
226,sirt1,protein,,sirt1,uniprot,q96eb6,,,p-38,protein,,mapk11,uniprot,q15759,,,positive,d,activation,,,,,,['962'],nan,nan,"p < 0.05 vs. il-1β-con. b elevated sirt1 expression increased erk activation and decreased jnk and p-38 activation in vivo. n = 6/group, **p < 0.01 vs. the sham group; #",pmc5372348,1,100,40,1,140
227,sirt1,protein,,sirt1,uniprot,q96eb6,,,p38mapk,protein,,mapk14,uniprot,q16539,,,positive,d,upregulation,,,,brain,human,['961'],nan,nan,sirt1 overexpression upregulated erk activation and downregulated jnk and p38mapk activation induced by il-1β-stimulation in vitro and brain injury in vivo,pmc5372348,1,100,40,1,140
228,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,inhibition,,,neural,brain,human,['970'],nan,nan,"elevating sirt1 expression and inhibiting erk, jnk, or p38mapk pathway activation improved the neurobehavioral function after brain injury",pmc5372348,1,100,40,1,140
181,ptprs,protein,,,uniprot,p23471,,,erk,protein,,mapk1,uniprot,p28482,,,positive,d,phosphorylation,,hct116,colorectal,,human,['318'],nan,nan,"since our data showed that loss of ptprs increased the phosphorylation of erk in tumor cells driven by both mutant kras as well as wild-type kras, we sought to further confirm the effects of ptprs knockout (ko) on crc cells, independent of kras mutation status. we compared the parental hct116 cell line (kras g13d/+) with one activated kras allele to its isogenic, engineered derivative hct116 (−/+) in which the activated kras allele was deleted, leaving the cell lines with only one wild-type kras allele. in each of these two cell lines, ptprs was knocked out by crispr and paired with crispr controls. cells from growing cultures of these paired cell lines were harvested. extracts were then prepared and activated erk was measured by western blots of phosphorylated erk. figure 4a shows that the cells without ptprs had an increased erk phosphorylation greater than its crispr control cell line. clearly, not only did the reduction of ptprs expression modulate the erk activity in cells with a mutant kras driven erk pathway, but an increase in erk activation was also seen in the cells with wild-type kras. while mutant kras hct116 (kras g13d/+) seemed to induce more phospho-erk than wild-type kras hct116 (−/+), the loss of ptprs did not bring about an elevated mek phosphorylation in either cell line.",pmc6006154,1,100,40,1,140
195,raf,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,d,phosphorylation,s727,h-rasv12 transformed mefs,fibroblast,,mouse,['15'],nan,nan,"to confirm that the raf-mek-erk pathway is engaged by activated ras to transduce phosphorylation of stat3 on s727, we titrated the dose of the mek-erk pathway inhibitor, pd0325901 [25]. treatment of h-rasv12 transformed mefs with increasing concentrations of pd0325901 from 50-1000 nm impaired erk phosphorylation, but had no impact on akt phosphorylation (figure 1c). importantly, treatment with doses of pd0325901 ranging from 50-1000nm completely inhibited s727 phosphorylation of stat3, indicating that the raf-mek-erk pathway is necessary for stat3 phosphorylation in the context of ras-transformation.",pmc3843736,1,10,38,1,48
154,p38 mapk,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,c-raf,protein,,raf1,uniprot,p04049,plasma membrane,go:0005886,negative,d,inhibit,,,,,cells,['460'],nan,nan,"several studies [16,20] have shown that in some types of cells, p38 mapk can inhibit the c-raf → mek1/2 → erk1/2 (extracellular signal-regulated kinases 1 and 2) pathway, i.e., the erk signaling pathway. the erk pathway is mostly activated by growth factors. these factors, acting through receptor kinases and adaptor protein son of sevenless (sos), activate ras gtpase, which is responsible for c-raf phosphorylation [21]. like p38 mapk, the erk pathway can affect various proteins associated with apoptosis, e.g., fox03a or several proteins of the bcl-2 family [22]. it has been demonstrated that the erk pathway can mediate both pro-apoptotic as well as anti-apoptotic signaling [23,24,25,26]. regulation of erk1/2 activation by saturated fas in pancreatic β-cells has also been shown [27,28].",pmc4783893,1,10,38,1,48
196,raf,protein,,raf1,uniprot,p04049,,,erk,protein,,mapk1,uniprot,p28482,,,positive,d,activation,,mouse fibroblasts,fibroblast,,mouse,['501'],nan,nan,"activation of the raf-mediated erk pathway by oncogenic ras induces transformation in mouse fibroblasts (kolch et al., 1991; cowley et al., 1994; mansour et al., 1994). because the activation of erk was abrogated by da-raf1 expression, we examined whether the v–k-ras–induced transformed phenotype in nrt9 cells was suppressed by da-raf1. normal nih3t3 cells contained well-developed actin stress fibers and showed an extended flattened cell shape. although nrt9 cells exhibited transformed morphology (i.e., the loss of stress fibers and consequent round cell shape), all of the nrt/dr cell lines restored the normal flattened cell shape with stress fibers (fig. 4 b). next, we analyzed the cell proliferation rate under a serum starvation condition in 0.5% fbs by counting the cell number. nrt9 and mock-transfected nrt9 cells showed growth rates several fold higher than that of normal nih3t3 cells, whereas all of the nrt/dr cell lines exhibited growth rates similar to or lower than that of nih3t3 cells (fig. 4 c).",pmc2064279,1,10,38,1,48
247,tgf-β1,protein,,tgfb1,uniprot,p01137,extracellular region,go:0005576,da-raf,protein,,araf,uniprot,p10398,plasma membrane,go:0005886,positive,d,induction,,rle cells,respiratory epithelial,lung,rat,['820'],nan,nan,"(a) induction of the binding of da-raf to ras by tgf-β1 stimulation. the binding was analyzed by a coimmunoprecipitation assay. rle cells were treated with 0.5 ng/ml tgf-β1 for 5 min. da-raf was immunoprecipitated with anti-da-raf pab, and coprecipitated ras was detected by immunoblotting with pan-ras mab. (b) elevation of the phosphorylation levels of mek and erk by da-raf knockdown. rle cells were transfected with daraf sirna1 as well as the control sirna and treated with 0.5 ng/ml tgf-β1 for the indicated time. the levels of mek, p-mek, erk, p-erk, da-raf, a-raf, and β-tubulin were analyzed by immunoblotting. the relative intensities of p-mek1/2 and p-erk1/2 bands are indicated under their blots. (c) recovery of daraf sirna-blocked αsma expression with u0126. rle cells were transfected with daraf sirna1 or sirna2 and then treated with 2 or 5 μm u0126 and 0.5 ng/ml tgf-β1 for 48 h. the level of αsma, as well as β-tubulin as a standard, was analyzed by immunoblotting. (d) recovery of daraf sirna-impaired αsma expressing cells with u0126. rle cells were transfected with daraf sirna1 or sirna2 and then treated with 5 μm u0126 and 0.5 ng/ml tgf-β1 for 48 h. αsma expression (red) and nuclei (blue) were detected. scale bar, 50 μm. (e) the ratio of αsma-expressing cells in the analysis of (d). the values are means ± sd of 3 independent experiments. *, p < 0.05; **, p < 0.01; #, p > 0.05 (not significant) by t test.",pmc4440819,1,10,38,1,48
246,tgf-β1,protein,,,uniprot,p01137,extracellular,go:0005576,smad2/3,protein,,,uniprot,q15796,cytoplasm,go:0005737,positive,d,signaling,,rle cells,epithelial,lung,human,['828'],nan,nan,"(a) tgf-β1-induced smad2/3 signaling is essential for emt from rle cells to myofibroblasts expressing αsma, collagen 1, and fibronectin. tgf-β1-induced ras activity is weak, and intrinsic da-raf is sufficient to suppress the erk pathway by binding to activated ras. (b) fgf2 stimulation (as well as fgf1 or hgf stimulation) or overexpression of the constitutively active ras, raf, or mek intensifies the activity of the ras—erk pathway activated by tgf-β1. intrinsic da-raf is not sufficient to overcome the strong ras—erk pathway activity. activated erk might interfere with the nuclear translocation of smad2/3, which is required to induce emt.",pmc4440819,1,10,38,1,48
238,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,s727,thp-1,myeloid,leukemia,human,['16'],nan,nan,"phosphorylation of stat3 on s727 in ras-transformed mefs and its inhibition by treatment with mek inhibitors provided strong evidence for a role for ras-activated mapk in stat3 s727 phosphorylation. to extend these results from experimental murine cells to human tumor cells, we examined the stat3 s727 phosphorylation and its inhibition by pd0325901 in the human acute myelocytic leukemia cell line, thp-1, which express mutant n-ras [26]. extracts from thp-1 cells displayed constitutively phosphorylated erk (figure 1d, panel 3, lane 1), as expected for n-ras-transformed cells. in addition, these cells expressed stat3 constitutively phosphorylated on s727 (figure 1d, panel 1, lane 1). treatment of cells with concentrations of the mek inhibitor pd0325901 between 50 and 1000 nm led to the inhibition of phospho-erk (figure 1d, panel 3, lanes 2-5) and the simultaneous loss of stat3 ps727 (panel 1, lanes 2-5). similar to the effects of mek inhibition observed in mouse cells, treatment of thp-1 cells with pd0325901 strongly inhibited perk at 50 nm and completely inhibited its phosphorylation at higher doses, without affecting total erk protein levels. stat3 ps727 was completely inhibited by all tested doses of pd0325901 without affecting total stat3 expression, again paralleling the observations in mouse cells (compare figure 2c and 2d). these data support the conclusion that ras-dependent stat3 s727 phosphorylation is mek dependent in tumors of both mouse and human origin.",pmc3843736,1,10,38,1,48
236,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,rps6,protein,,rps6,uniprot,p62753,cytoplasm,go:0005737,positive,d,phosphorylation,,,,thyroid,human,['890'],nan,nan,"taken together, our data provides a critical piece of information in regards to the role of src in thyroid cancer, and the patient populations most likely to respond to the combined inhibition of src and the mapk pathway. in addition, the identification of rps6 phosphorylation as a biomarker of response to the combined inhibition of src and the mapk pathway provides an important tool for the identification of drug tolerant persisters, and the future determination of pathways that mediate resistance to this combination strategy. finally, we predict that the discoveries presented in this study will pave the way for improved responses, and enhanced overall survival for patients with advanced papillary and anaplastic thyroid cancer.",pmc5833015,1,10,38,1,48
235,src,protein,,,uniprot,p12931,,,akt,protein,,,uniprot,p31749,,,positive,d,expression,,,,,,['867'],nan,nan,"to identify thyroid cancer cell lines sensitive or resistant to dasatinib, we analyzed the sensitivity of 36 thyroid cancer cell lines, to the src inhibitor dasatinib, using an ic50 cutoff of 90 nm, which is based on the peak plasma/serum concentrations of dasatinib in patients treated for chronic myelogenous leukemia, as well as the selectivity of dasatinib (fig. 1a)22. interestingly, there appears to be an additional separation in the resistant group (90 nm), which may demarcate intermediate and higher levels of resistance. we next performed reverse phase protein analysis (rppa) to determine signaling differences between the sensitive and resistant groups, and used elastic net regression analysis to identify proteins whose expression is associated with the sensitivity (positive coefficients) and resistance (negative coefficients) to dasatinib (fig. 1b). the cross-validation of the elastic net model indicated that protein expression data obtained with rppa indeed explains the sensitivity to dasatinib (elastic net model was superior to the null model) (figure s1a). in support of this, expression of src was the major protein associated with sensitivity to dasatinib (fig. 1b). we next analyzed proteins enriched in cell lines resistant to dasatinib, and observed numerous proteins associated with the pi3k pathway and downstream effectors of akt. to further delineate a correlation between pi3k pathway activation and increasing resistance to dasatinib, we performed clustering analysis of the phosphorylated antibodies quantified using rppa. we identified a cluster of phosphoproteins, in which expression is enriched with increased resistance to dasatinib (fig. 1c; denoted with red lines). analysis of this cluster contained many proteins predictive of dasatinib resistance in the elastic net regression model, as well as additional components of the pi3k pathway (akt ps473, akt t308, mtor ps2448, p70s6k t389, 4ebp1 ps65, s6 s235/236, and s6 s240/244) and downstream targets of akt (tuberin pt1462 and yb1 ps102; fig. 1d).",pmc5833015,1,10,38,1,48
221,rps6,protein,,rps6,uniprot,p62753,cytoplasm,go:0005737,pik3ca,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,negative,d,inhibition,,8505c and c643,thyroid cancer,thyroid,human,['884'],nan,nan,"having observed that a subset of the 8505c and c643 cells maintain rps6 phosphorylation upon treatment with the combination therapy (fig. 5b), we hypothesized that more effective inhibition of rps6 phosphorylation may potentiate the cytotoxic effects in these cell lines. on the basis of our observations in fig. 2, in which pik3ca-mutant cell lines were resistant to the combination therapy, we next tested the effects of src and mek1/2 inhibition in combination with an akt/p70s6k inhibitor, at7867. due to the high potency of this triple combination, a shorter (4 h) time point was used for this experiment. interestingly, in contrast to longer treatments (24 h in figs. 2 and 4), single-agent treatment with trametinib for 4 h results in higher levels of ps6, pfak, and pakt in the 8505c cells, and ps6-s240/244 in the c643 cells. nonetheless, combined inhibition of both the mapk and the pi3k pathways, with trametinib and dasatinib, with or without at7867, respectively, correlates with reduced rps6 phosphorylation and enhanced inhibition of growth and increased apoptosis (fig. 6a–c). important for future considerations, is the observation that the combined inhibition of src and akt/p70s6k results in the largest decrease in rps6 phosphorylation in comparison to the other dual inhibitory combinations (fig. 6a and s5a), however this decrease in rps6 phosphorylation does not correlate with a similar increase in apoptosis or a decrease in cell growth (fig. 6b, c and s5b). taken together, rps6 phosphorylation status appears to be an important indicator for the effectiveness of combined mapk and src/pi3k pathway inhibition.",pmc5833015,1,10,38,1,48
219,ras,protein,oncogene,ras,uniprot,p01112,cytoplasm,go:0005737,mek,protein,kinase,map2k1,uniprot,p36507,cytoplasm,go:0005737,positive,d,phosphorylation,,dld-1 cells,epithelial,colon,human,['1048'],nan,nan,"as oncogenic ras signaling supports anchorage-independent growth in vitro [5, 12, 14], a hallmark of oncogenic transformation, we investigated the effects of foxo3, tcf7l2, and ncoa3 shrna knockdown on anchorage-independent growth by colony formation in soft agar. we observed more than twofold reduced anchorage-independent growth in dld-1 cells with kras g13d mutation and activated oncogenic ras signaling (fig. 3a and additional file 1: figure s10a) while the rates of growth in normal medium and colony formation on plastic were similar (fig. 3b, c; additional file 1: figure s10b). however, the rko (braf v600e) cells did not form colonies in the same soft agar assay. mutational or expression changes in genes of the egfr/ras/mapk pathway can alter the cellular ratios of phosphorylated mek to total mek and of phosphorylated erk to total erk [25, 26]. stable knockdown of foxo3 or tcf7l2 reduced pmek and perk in dld-1 cells with kras g13d mutation and rko cells with braf v600e mutation, to an extent similar to knockdown of kras or braf (fig. 3c–f; additional file 1: figure s11a, b and additional file 1: figure s12a, b). while knockdown of ncoa3 had little effect on pmek/mek and no effect on perk/erk ratios in dld-1 cells with kras g13d mutation (fig. 3c and e; additional file 1: figure s11a, b), it had significant effect in rko (braf v600e) cells (fig. 3d and f; additional file 1: figure s12a, b). hence, stable knockdown of foxo3, ncoa3, and tcf7l2 significantly reduced anchorage-independent growth and mek/erk phosphorylation.",pmc5755028,1,10,38,1,48
218,ras,protein,,ras,uniprot,p01116,plasma membrane,go:0005886,mek,protein,,mek,uniprot,q02750,cytoplasm,go:0005737,negative,d,inhibition,,,,,,['738'],nan,nan,"al, mn, mc, tz, hd and jw performed data analysis, interpreted results, and created figures for the manuscript. rk and jf performed acquired resistance studies. ba and br led cell line drug response experiments. bh and mc led experiments to assess ras signature inhibition after mek inhibitor treatment. ja and kn performed kras sirna studies. cp and bl performed reverse phase protein array experiments. ph provided scientific direction, critical review, and data interpretation. jw led authoring of the manuscript. all authors read and approved the final manuscript.",pmc2911390,1,10,38,1,48
217,ras,protein,,ras,uniprot,p01116,plasma membrane,go:0005886,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,d,regulation,,,,,colorectal cancer,['305'],nan,nan,"colorectal cancer (crc) growth and progression is frequently driven by ras pathway activation through upstream growth factor receptor activation or through mutational activation of kras or braf. here we describe an additional mechanism by which the ras pathway may be modulated in crc. ptprs, a receptor-type protein tyrosine phosphatase, appears to regulate ras pathway activation through erk. ptprs modulates erk phosphorylation and subsequent translocation to the nucleus. native mutations in ptprs, present in ~10% of crc, may reduce its phosphatase activity while increasing erk activation and downstream transcriptional signaling.",pmc6006154,1,10,38,1,48
216,ras,protein,,ras,uniprot,p01112,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,activation,,,colorectal cancer,,human,['337'],nan,nan,"ras and its downstream effectors have been targeted to develop therapeutic inhibitors in various cancers with frequently mutated kras or braf54–56. although efforts to directly target ras have not been successful to date, selective braf and/or mek inhibitors have shown clinical efficacy in braf-mutant melanoma56. more recently, specific inhibitors of erk have been also developed, which appear to hold promise to overcome acquired resistance to mek inhibitors56–60. it is noteworthy that the combination of meki with the pi3k/akt/mtor inhibitors has been conducted in preclinical studies and in clinical trials61. our study revealed that inactivation of ptprs enhanced the activation of erk and akt, which may facilitate the development of effective targeted therapies against erk and/or akt in colorectal cancer.",pmc6006154,1,10,38,1,48
214,ras,protein,,ras,uniprot,p01112,,,mek,protein,,map2k1,uniprot,q02750,,,negative,d,inhibition,,,fibroblast,lung,"rat, human",['58'],nan,nan,"the ras-raf-mek-erk pathway plays a central role in tumorigenesis and is a target for anticancer therapy. the successful strategy based on the activation of cell death in ras-expressing cells is associated with the suppression of kinases involved in ras pathway. however, activation of cytoprotective autophagy overcomes antiproliferative effect of the inhibitors and develops drug resistance. we studied whether cellular senescence induced by hdac inhibitor sodium butyrate in e1a+cha-ras-transformed rat embryo fibroblasts (eras) and a549 human ki-ras mutated lung adenocarcinoma cells would enhance the tumor suppressor effect of mek/erk inhibition. treatment of control eras cells with pd0325901 for 24 hresults in mitochondria damage and apoptotic death of a part of cellular population. however, the activation of ampk-dependent autophagy overcomes pro-apoptotic effects of mek/erk inhibitor and results in restoration of the mitochondria and rescue of viability. senescent eras cells do not develop cytoprotective autophagy upon inhibition of mek/erk pathway due to spatial dissociation of lysosomes and autophagosomes in the senescent cells. senescent cells are unable to form the autophagolysosomes and to remove the damaged mitochondria resulting in apoptotic death. our data show that suppression of mek/erk pathway in senescent cells provides a new strategy for elimination of ras-expressing cells.",pmc5723691,1,10,38,1,48
213,ras,protein,,ras,uniprot,p01112,,,mek,protein,,map2k,uniprot,p36507,,,positive,d,activation,,,,childhood acute lymphoblastic leukemia,human,['756'],nan,nan,"deregulation of the ras/raf/mek/extracellular signal-regulated kinase pathway is a common event in childhood acute lymphoblastic leukemia and is caused by point mutation, gene deletion, and chromosomal translocation of a vast array of gene types, highlighting its importance in leukemia biology. pathway activation can be therapeutically exploited and may guide new therapies needed for relapsed acute lymphoblastic leukemia and other high risk subgroups.",pmc4067595,1,10,38,1,48
207,ras,protein,,,uniprot,p01112,,,stat3,protein,,stat3,uniprot,p40763,,,positive,i,phosphorylation,s727,,,,,['36'],nan,nan,ras induced phosphorylation of stat3 s727 through an erk dependent pathway supports transformation,pmc3843736,1,10,38,1,48
205,ras,protein,,hras,uniprot,p01112,,,stat3,protein,,stat3,uniprot,p40763,mitochondria,go:0005739,positive,i,transformation,mitochondria,mefs,fibroblast,,,['20'],nan,nan,"we previously found that ras transformation is dependent on a mitochondrial pool of stat3, and that s727 phosphorylation of this pool of stat3 is critical for maintaining a transformed phenotype [12]. therefore, to define whether ras activation of the raf-mek-erk pathway and the consequent s727 phospohorylation of the mitochondrial pool of stat3 was important for transformation, we performed colony assays as a measure of anchorage independent cell growth. stat3-null cells stably expressing the h-rasv12 effector domain mutations were reconstituted with either wild-type stat3, a stat3 mutant that is exclusively expressed in mitochondria, or mitochondrial stat3 harboring a serine to aspartic acid point mutation intended to mimic phosphorylation of s727. these cells were plated in soft agar to measure anchorage independent growth. consistent with our previous data, we observed that h-rasv12 transformed mefs formed colonies in soft agar, while loss of stat3 largely abolished anchorage independent growth (figure 2a). we next addressed whether h-rasv12 was capable of maintaining a transformed phenotype when restricted to signaling individually through the raf-mek-erk or the pi3k pathway. therefore, we plated mefs stably expressing h-rasv12/35s or h-rasv12/40c in soft agar. similar to h-rasv12, neither h-rasv12/40c nor h-rasv12/35s supported colony formation in the absence of stat3 (figure 2a, compare bar 1 to 3 and 6). however, when h-rasv12/35s-expressing stat3-/- mefs were engineered to express a mutant form of stat3 exclusively localized to mitochondria (mts-stat3), they formed significantly (p<0.05) more colonies than rasv12/35s transduced, stat3-/- mefs (figure 2a, compare bar 3 to 4). in contrast, the mitochondrial form of stat3 did not increase colony formation in h-rasv12/40c transduced cells (figure 2a, compare bars 6, 7 and 8).",pmc3843736,1,10,38,1,48
204,ras,protein,,hras,uniprot,p01112,cytoplasm,go:0005737,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,i,phosphorylation,s727,mef,fibroblast,embryo,murine,['10'],nan,nan,"ras engages numerous signaling pathways to elicit its tumorigenic activities, primarily the mek-erk, phosphoinositol-3-kinase (pi3k), and ral pathways [20]. activation of each single pathway is sufficient to induce limited cell transformation in vitro, and we have previously found that transformation of murine embryo fibroblasts (mef) in vitro by each ras-activated pathway is stat3 dependent [12]. moreover, while activation of each of these pathways in isolation is insufficient to fully transform cells, combined activation of the mek-erk and pi3k pathways transformed cells equivalently to h-rasv12 [12]. because ras transformation required stat3 s727 phosphorylation, it was of interest to determine which ras signaling pathway was responsible for this post-translational modification.",pmc3843736,1,10,38,1,48
202,ras,protein,h-rasv12,hras,uniprot,p01112,cytoplasm,go:0005737,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,i,phosphorylation,s727,,cancer,,human,['13'],nan,nan,"consistent with our previous data we found that activation of ras (h-rasv12) led to s727 phosphorylation, but not y705 phosphorylation of stat3 (figure 1a). interestingly, we detected stat3 s727 phosphorylation in cells where only the raf-mek-erk pathway was active, but not in cells with activated pi3k alone, in spite of clear evidence of activation of akt (figure 1a).",pmc3843736,1,10,38,1,48
201,ras,protein,gtpase,ras,uniprot,p01112,plasma membrane,go:0005886,erk,protein,kinase,mapk1,uniprot,p28482,nucleus,go:0005634,positive,d,activation,,,,,,['757'],nan,nan,"the core of the signaling pathway comprises three dual-specific protein kinases raf, mek, erk, and the g-protein ras. the ras family contains three genes hras, nras, and kras that encode 21 kda proteins. the kras transcript undergoes alternate splicing thus resulting in four ras protein isoforms (hras, nras, kras4a, kras4b). ras proteins are monomeric membrane-associated gtpases, which communicate binary on or off messages to downstream effector proteins by cycling between an active gtp bound and inactive gdp bound state. ras activation is catalyzed by guanine nucleotide exchange factors (gefs), such as son of sevenless (sos), which displace gdp and allow gtp to preferentially occupy the vacant nucleotide binding site due to its relative abundance in the cytoplasm. ras proteins exhibit intrinsic low-level hydrolytic activity and are negatively regulated by gtpase activating proteins (gaps) such as neurofibromin (nf1), which stimulate gtp hydrolysis and formation of inactive ras–gdp (figure 1).",pmc4067595,1,10,38,1,48
199,ras,protein,g-protein,hras,uniprot,p01112,cytoplasm,go:0005737,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,activation,,,breast cancer,,human,['1238'],nan,nan,"breast cancer is the most frequently diagnosed female cancer and represents the second most common cause of female cancer-related deaths in the world [1]. furthermore, it accounts for the most morbidity and the fourth highest mortality of female cancers in taiwan [2]. the ras/erk pathway (also known as the mitogen-activated protein kinase (mapk)/erk pathway or the ras-raf-mek-erk cascade) has been reported to play an essential role in tumorigenesis and cancer progression [3, 4]. hyperactivation of the ras/erk pathway has been reported in approximately half of breast cancer cases [5, 6] and significantly associated with the aggressive behavior and poorer prognosis of breast cancer [7–9]. in addition, ras/erk pathway hyperactivation is a common feature of a variety of tumor types with activating mutations in kras, nras, or braf [10]; however, mutations in these genes were detected in only ~3.2% of all breast lesions [11]. nevertheless, most ras/erk signaling molecules are often overexpressed in breast cancer [12], suggesting that there are other genomic and/or epigenetic regulations involved in the aberrant activation of the ras/erk pathway [5, 7, 13].",pmc5410235,1,10,38,1,48
197,raf,protein,,raf1,uniprot,p04049,,,stat3,protein,,stat3,uniprot,p40763,mitochondria,go:0005739,positive,i,co-operates,mitochondrial,,,,,['19'],nan,nan,the raf-mek-erk but not the pi3k-akt pathway co-operates with mitochondrial-stat3 in ras-mediated transformation,pmc3843736,1,10,38,1,48
155,p38 mapk,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,positive,d,cleavage,,,,,,['478'],nan,nan,"because cell death was induced, we also tested the effect of p38 mapk activation on the cleavage of parp (a common marker of apoptosis) and caspase-7, -8 and -9 activation. caspase-7, -8, -9 activation as well as parp cleavage was detected 12 h after activator application (figure 5d).",pmc4783893,1,10,38,1,48
2,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,mapk,protein,,mapk3,uniprot,p27361,cytoplasm,go:0005737,positive,d,signaling,,,gastric,stomach,human,['774'],nan,nan,gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via akt and mapk signaling pathways,pmc5729429,1,10,38,1,48
74,erk,protein,,mapk1,uniprot,p28482,nucleus,go:0005634,ras,protein,mutant,hras,uniprot,p01112,plasma membrane,go:0005886,negative,d,inhibition,,,cancer,,human,['681'],nan,nan,"“with respect to clinical applications, we here report that effective inhibition of the egfr-mek-erk pathway through combinatorial targeting does significantly prime the cytostatic ras mutant cancer cells for apoptosis. […] nevertheless, we consider the navitoclax-induced apoptosis as a proof-of-principle that egfr-mek-erk pathway inhibition in combination with alternative signaling nodes holds great promise in identifying therapeutic drug combinations that kill ras mutant tumor cells while being tolerated by the patient.”",pmc5127645,1,10,38,1,48
120,mapk,protein,mitogen-activated protein kinase,mapk,uniprot,p28482,cytoplasm,go:0005737,mek2,protein,,map2k2,uniprot,p36507,cytoplasm,go:0005737,positive,d,inhibition,,,melanoma cells,melanoma,human,['136'],nan,nan,"the mitogen-activated protein kinase (mapk) pathway is a critical oncogenic driver signal in a number of malignancies. the discovery of activating mutations in the mapk pathway has led to the development of mapk pathway inhibitors. selumetinib is a potent and selective inhibitor of mek1 and mek2, which are essential downstream molecules in the mapk pathway. several preclinical and clinical studies have demonstrated the promising antitumor activity of selumetinib. in this review, we discuss the mapk pathway in melanoma and summarized data from preclinical and clinical studies of selumetinib for advanced melanoma.",pmc4179759,1,10,38,1,48
113,kras,protein,oncogene,kras,uniprot,p01116,plasma membrane,go:0005886,glut1,protein,transporter,slc2a1,uniprot,p11166,plasma membrane,go:0005886,positive,d,gene mutagenesis,glucose metabolism,dld-1 kraswt/-,colorectal,colorectal cancer cell,human,['1040'],nan,nan,"to discover genes in the ras pathway, we transposon mutagenized human crc cells having had their active kras or braf oncogene removed by genome editing and used a two-step selection procedure where: (1) tolerance to low glucose was selected by culturing three weeks in medium with 0.4 mm l-glucose; and (2) the resulting clones were selected for having productive transposon integrations by culture in hygromycin-containing medium (additional file 1: figure s1). the hygromycin selection serves to eliminate background clones generated by transposon-independent mechanisms, such as those having acquired kras and braf hotspot mutations through the endogenous mmr deficiency [6]. next, the gene set with recurring transposon integrations is intersected with genes observed mutated in human crcs to select candidate ras pathway genes for experimental validation. mutagenesis of dld-1 kraswt/- and rko brafwt/-/- cell lines with transposase and transposon constructs (additional file 1: figure s2a–c) followed by selection in low glucose and hygromycin resulted in sixfold to 22-fold more clones than transposon constructs alone (fig. 1a and b; additional file 1: figure s3), demonstrating that transposon mutagenesis could restore growth in low-glucose medium. the majority of selected clones (13/16) and all clone pools had twfold to sixfold higher glut1 expression, a biomarker for ras pathway activation in human crc cells [6] compared to dld-1 kraswt/- and rko brafwt/-/- cells (fig. 1c and d). two gene trap libraries (pb-gt) of 1500 and 2000 clones each, as well as two individual activation libraries (pb-cag-sd) of 3000 and 2480 clones each in dld-1 kraswt/- and rko brafwt/-/- cells, respectively (fig. 1c and d), were subjected to sequencing. the clone pools were analyzed by splinkerette pcr amplification followed by sequencing of transposon integration sites, resulting in 2029 genes in dld-1 kraswt/- and 2887 genes in rko brafwt/-/- pools having more frequent integrations than expected given their ttaa site density (p ≤ 0.05, poisson distribution) on all the chromosomes (additional file 1: figure s4; additional file 1: table s1 and s2; additional file 1: figure s5).",pmc5755028,1,10,38,1,48
110,kras,protein,,kras,uniprot,p01116,plasma membrane,go:0005886,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,positive,d,phosphorylation,,hct116,colorectal,colon,human,['319'],nan,nan,"comparison of isogenic hct116 cell lines with and without activated kras. (a) the parental crc hct116 (kras g13d/+) cell line has an activating mutation of kras. here we compare this cell line to an isogenic hct116 (−/+) cell line that has the mutated kras allele knocked out, leaving the cell with only one wt kras allele. ptprs crispr ko and crispr control paired cell lines were made in both hct116 parental (kras g13d/+) and the isogenic hct116 (−/+) cell lines. extracts prepared from growing cultures were used for western blot analysis of erk, phospho-erk, mek, phospho-mek, akt andphospho-akt. the hct116 (−/+) is shown to have natively less phospho-erk compared to its parental hct116 cell line with the activated kras mutation. the ko of ptprs for both cell lines shows a dramatic increase in phospho-erk and phospho-akt. quantitations were determined by normalizing the phosphorylated protein values with the total protein; then dividing the ptprs ko by the crispr control values. all experiments were done in triplicate. the mean and standard deviation are shown. two-tailed, paired t test was used to determine the statistical significance for comparison as indicated. (b) active ras pull down for all cell lines. the mutant kras cells lines, hct116 and sw620, show a constitutively active ras. the wt kras",pmc6006154,1,10,38,1,48
51,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0016020,mek,protein,,map2k1,uniprot,p36507,cytoplasm,go:0005737,negative,d,inhibition,,,organoid,,human,['697'],nan,nan,"8) the authors conclude that the inhibition of the egfr/mek/erk axis induces mostly a cell cycle arrest that, in absence of drug, can be reverted and cells proliferate again. i would be more cautious in this affirmation, given the data presented. it is not clear from the data presented whether there is a global cell cycle stop (no assessment of g1/s checkpoint activation nor cell cycle progression markers) and the data does not rule out the possibility of a small population of pre-resistant cells within the organoid, which are then able to repopulate in absence of treatment.",pmc5127645,1,10,38,1,48
103,kras,protein,mutant,kras,uniprot,p01116,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,inhibition,cell cycle,,tumor,,human,['684'],nan,nan,we strengthened our evidence that kras mutant tumor cells are blocked in cell cycle progression upon inhibition of the egfr-mek-erk pathway. these data are now included as a new figure 8.,pmc5127645,1,10,38,1,48
100,k-rasg12v,protein,,kras,uniprot,p01116,cytoplasm,go:0005737,stat3,protein,mitochondrial,stat3,uniprot,p40763,mitochondria,go:0005739,positive,i,phosphorylation,s727,,,,human,['31'],nan,nan,k-rasg12v transformation requires the mek-erk pathway and s727 phosphorylation of mitochondrial stat3.,pmc3843736,1,10,38,1,48
99,k-ras,protein,,kras,uniprot,p01116,plasma membrane,go:0005886,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,i,phosphorylation,s727,,fibroblast,,human,['5'],nan,nan,"in this study, we used genetic mutants and pharmacological inhibitors to show that h-, n- and k-ras engage the raf-mek-erk pathway to cause phosphorylation of stat3 on s727, which is necessary for the anchorage-independent growth of transformed fibroblasts as colonies in soft agar. moreover, we show that a stat3 mutant that mimics s727 phosphorylation (s727d) is partially refractory to the block in transformation resulting from pharmacologic inhibition of the raf-mek-erk mapk pathway.",pmc3843736,1,10,38,1,48
52,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,erk,protein,,erk,uniprot,p27361,cytoplasm,go:0005737,positive,d,inhibition,,,colorectal cancer,,human,['644'],nan,nan,"another important observation after comparative analysis on this wide crc panel concerns patient-to-patient variability in the response to anti-egfr monotherapy, even within the ras wt and mutant subgroups (figure 6b, upper left). combining egfri with either mek or erki results in a more consistent inhibitory effect over this set of crcs (figure 6b, lower panels), thereby not only improving individual responses but also augmenting success rates on a population scale. these findings are supportive to the previously published concept that proposes to combine egfr with mek inhibition directly at the start of therapy in patients with wt ras tumors with the rationale of preventing sub-clones with acquired resistance to anti-egfr monotherapy from reigniting tumor growth (misale et al., 2015).",pmc5127645,1,10,38,1,48
96,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,activation,,,,,,['599'],nan,nan,"taken together, as shown in fig. 7 c, it is speculated that oxidative stress induce cell death partly through activating the jnk pathway which has been known to be able to trigger apoptotic cascade. in contrast, erk that promotes cell survival is also activated during ros stress to balance the cell death. in this context, page4 protect cells from oxidative stress potentially by reducing cell death message while enhancing cell survival signals.",pmc6339303,1,10,38,1,48
53,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,inhibition,,,organoid,"colon, small intestine",human,['642'],nan,nan,"(a) dose-response curves of 11 different patient-derived crc organoids and one engineered crc organoid (p18t-krasg12d) treated for 72 hr with single targeted inhibitors or combinations thereof, namely afatinib (dual egfr/her2 inhibitor), selumetinib (mek inhibitor) and sch772984 (erk inhibitor). 5 crc organoids contain wt kras (green lines), 5 crc organoids contained annotated oncogenic kras mutations (red lines), p19bt contains an oncogenic version of braf and p25t contains an oncogenic mutation in nras (purple and blue lines, resp.). see figure 6—source data 1 and supplementary file 1 for all dose-response curves. (b) crc and normal organoids classified based on the mutational status of the ras-raf-mek-erk signaling pathway. responses to afatinib, selumetinib, sch772984 and combinations thereof, are shown in scatter plots of ic50 values (μm; 10log scale). each colored dot represents an individual organoid line. note that the experiment included normal organoids from the colon as well as the small intestine (three individual persons). color corresponds as indicated in the legend. black bar is the geometric mean. n.s., not significant. *p<0,05. **p<0,01.",pmc5127645,1,10,38,1,48
54,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,,hct116,epithelial,colon,human,['325'],nan,nan,"the activation of egfr and erk in ptprs knockout cell lines and in response to egf stimulation. (a) the crc ptprs crispr ko cell lines sw620, km12l4a, hct116 [mutant kras g13d/+], and hct116 [wt kras −/+] and their crispr control cells were cultured, and harvested for western blotting to determine the phosphorylation of egfr. phosphorylation of egfr y1173, y1068 and total egfr are shown. quantitations were done normalizing each phospho-egfr levels against total egfr levels; normalized phospho-egfr values for the ko were then divided by the control values to see the fold change difference. sw620 shows no egfr expression revealing that egfr appears to be not the driving mechanism of the observed change in phospho-erk. hct116 [kras g13d/+] also shows no change in egfr phosphorylation. the wt kras cell lines, km12l4a and hct116 [wt kras −/+] do show a change in phospho-egfr. all experiments were done in triplicate. the mean and standard deviation are shown. two-tailed, paired t test was used to determine the statistical significance for comparison as indicated. (b) time course of serum starved hct116 parental [mutant kras, g13d/+] ptprs crispr ko and crispr control cells treated with egf (50 ng/ml). at the times indicated, cells were harvested and extracts were prepared for western blotting. egfr, egfr phosphorylated at y1173 andy1068, as well as erk, phospho-erk, akt and phospho-akt are shown. (c) hct116 wt kras [−/+] ptprs crispr ko and crispr control cells are shown with identical treatment as in (b). (d) this graph shows the normalized values of phospho-egfr (left panels, average of y1173 and y1068), phospho-erk (middle panels), and phospho-akt (right panels) for the blots shown in fig. 6b (top three panels) and fig. 6c (bottom three panels). all experiments were done in triplicate. the mean and standard deviation are shown. two-tailed, paired t test was used to determine the statistical significance for comparison. significant p values (<0.05) are shown; * − near significant p values.",pmc6006154,1,10,38,1,48
58,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,mek,protein,,mek,uniprot,q02750,cytoplasm,go:0005737,negative,d,inhibition,,,cancer,,human,['649'],nan,nan,"(a) representative cell cycle analysis of p18t-krasg12d and p26t by flow cytometry (n = 2). dna was stained with dapi and dna-synthesis was detected using a 3 hr edu pulse to clearly discriminate between g1, s and g2 stages of the cell cycle. dual inhibition of the egfr-mek-erk pathway significantly changes the distribution of cells between stages of the cell cycle (chi2: all p values<0,0001) with a predominant increase in g1 at the expense of cells in s-phase. egfri + meki = afatinib + selumetinib. meki + erki = selumetinib + sch772984. (b) almost no incorporation of edu (red) is detected during the last 24 hr of drug treatment using dual inhibition of the egfr-mek-erk signaling pathway, indicative of halted proliferative activity. nuclei are counterstained with hoechst (white). egfri + meki = afatinib + selumetinib. egfri + erki = afatinib + sch772984. scale bar is 100 µm. (c) virtually all cancer cells incorporate edu (red) when provided after release from targeted inhibition of the egfr-mek-erk pathway. nuclei are counterstained with hoechst (white). egfri + meki = afatinib + selumetinib. egfri + erki = afatinib + sch772984. scale bar is 100 µm. (d) chronological ranking of mitotic and apoptotic events extracted from live-cell imaging data of tumor recovery reconstructs the organoid size evolution over time. in contrast to vehicle treated organoids (blue lines), afatinib + selumetinib treated organoids (red lines) show first mitotic activity again from 20–24 hr onwards after drug withdrawal. typical snapshots of live-cell imaging data are provided. white circles indicate mitotic events. arrows indicate the organoid and moment of snapshot.",pmc5127645,1,10,38,1,48
64,egfr,protein,receptor,egfr,uniprot,p00533,cell membrane,go:0005886,mek,protein,kinase,map2k1,uniprot,q02750,cytoplasm,go:0005737,negative,d,inhibition,cell membrane,not specified,not specified,not specified,not specified,['709'],nan,nan,"subsection “dual inhibition of the egfr-mek-erk pathway induces a g1 cell cycle arrest”, last paragraph and legend to figure 8—figure supplement 1. “average growth speeds of the organoids were determined by linear fitting of the traces shown in figure 8d. the two time frames roughly correspond to the first half and the second half of the experiment. directly after drug removal, afatinib- and selumetinib-treated organoids show a significant reduction in growth speed as compared to vehicle-treated organoids. after 22-24 hrs of recovery, growth rates return to the level of vehicle-treated organoids (possibly even slightly faster). *, p<0,05; **, p<0,01; ***, p<0,001; n.s., not significant.”",pmc5127645,1,10,38,1,48
65,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,mek,protein,kinase,map2k1,uniprot,q02750,cytoplasm,go:0005737,negative,d,inhibition,egfr/mek/erk axis,,organoid,,,['672'],nan,nan,"8) the authors conclude that the inhibition of the egfr/mek/erk axis induces mostly a cell cycle arrest that, in absence of drug, can be reverted and cells proliferate again. i would be more cautious in this affirmation, given the data presented. it is not clear from the data presented whether there is a global cell cycle stop (no assessment of g1/s checkpoint activation nor cell cycle progression markers) and the data does not rule out the possibility of a small population of pre-resistant cells within the organoid, which are then able to repopulate in absence of treatment.",pmc5127645,1,10,38,1,48
66,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,raf,protein,kinase,raf1,uniprot,p04049,cytoplasm,go:0005737,positive,d,upregulation,,,,gastric cancer,human,['571'],nan,nan,"studied genes were selected from the (rtk)/ras/raf/mek/erk pathway described in kegg pathway “gastric cancer” (map05226). the pathway includes the following proteins (and the corresponding encoding genes): egfr (egfr), her2 (erbb2), shc (shc1), grb2 (grb2), sos (sos1, sos2), ras (hras, kras, nras), raf (araf, braf, raf1), mek (map2k1, map2k2), and erk1/2 (mapk1, mapk3). in addition to egfr and erbb2, we also included other tyrosine-kinase receptors that are known to trigger the ras/raf/mek/erk pathway and that are upregulated in gastric cancer: c-met (met), fgfr2 (fgfr2), her3 (erbb3), and pdgfr-β (pdgfrb). from the gsa array, the following criteria were used to select the snps for analysis: (1) located between 5 kb upstream from the transcription start site and 5 kb downstream from the stop triplet according to the grch37 assembly of the human genome; (2) minor allele frequency (maf) higher than 0.10; (3) not in linkage disequilibrium (ld) (r2 > 0.8) with other snps contained in the array; (4) with no departure from hardy–weinberg equilibrium (hwe) in the studied population (p < 0.01); (5) located in autosomes; and (6) have regulomedb score [20] 1 or 2 (themselves or their proxy snps) according to ad mixed american (amr) population data retrieved with ldlink 3.2.0 [21] from the 1000 genomes project phase 3 (version 5) data. no snps fulfilled all the criteria for the braf, sos2, nras, araf, and mapk3 genes. table s1 describes the list of 27 snps analyzed in this study.",pmc6356706,1,10,38,1,48
79,erk2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,d,interacts,,,,,human,['37'],nan,nan,"whilst stat3 s727 can be phosphorylated by many kinases, erk is the most common kinase implicated in this modification [8]. erk2 and stat3 interact [13] and the use of mek-erk inhibitors blocks stat3 s727 phosphorylation in response to il-2 [14]. in this study, we showed that stat3 is phosphorylated on s727 but not on y705 in the presence of activated h-ras. moreover, we showed that inhibition of the mek-erk pathway with pd0325901 reduced stat3 s727 phosphorylation to undetectable levels. inhibition of stat3 s727 phosphorylation was observed at the lowest concentrations of pd0325901 tested (50nm), at which erk phosphorylation was largely though not completely inhibited. this dose-response relationship suggests that effective erk activation is required for stat3 phosphorylation.",pmc3843736,1,10,38,1,48
69,erbb2,protein,,erbb2,uniprot,p04626,plasma membrane,go:0005886,cdkn2a,protein,,cdkn2a,uniprot,p42771,nucleus,go:0005634,positive,d,mutation,,,melanocytic,skin,human,['1210'],nan,nan,"two cases of mc (voa695 and voa439) were previously described to be heterogeneous for erbb2 amplification/overexpression [13]. as greater access was available for these local cases, a full series of clinical blocks was examined for erbb2 3+ and negative ihc. positive and negative regions were then fine-needle microdissected with both front and back erbb2-stained sections as a guide to ensure consistency in ihc positive (3+) and negative (0) regions. sequencing of the disparate regions of voa439 confirmed the previously observed kras p.gly12asp mutation at similar allelic frequency in both erbb2+ and erbb2- regions: 46.1 % and 43.5 % respectively (fig. 4). two tp53 and one cdkn2a mutations were also found in both regions at similar allelic frequencies. similar results were observed in case voa695 across erbb2+ and erbb2- regions: kras p.gly12asp mutation at 18.1 % and 16.6 %, and tp53 p. ser127pro mutation at 10.5 % and 19.6 % allelic frequency, respectively. double-hit ras-pathway alterations were confirmed in six additional mc cases (total 21.6 %). double-hits were observed in both mbot (two cases; 7.7 %) and mc, but were more prevalent in mc. in general, examination of allelic ratios of ras-pathway alterations in comparison to cellularity estimates suggested that ras-pathway mutations may be more likely to be hemizygous or homozygous (additional file 1) although copy number analysis was not available to validate this.",pmc4494777,1,10,38,1,48
70,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,jnk,protein,kinase,mapk8,uniprot,p45983,cytoplasm,go:0005737,negative,d,inhibition,,,,,human,['965'],nan,nan,"the results showed that u0126 significantly inhibited the erk activation but exerted no effect on the jnk or p38mapk activation in comparison to the dmso injection (p < 0.05 for erk; p > 0.05 for jnk and p38mapk; fig. 5b). similarly, p600125 significantly inhibited the jnk activation without affecting the erk or p38mapk activation as compared to the dmso injection (p < 0.05 for jnk; p > 0.05 for erk and p38mapk; fig. 5b). sb203580 significantly inhibited the p38mapk activation but showed no effects on erk or jnk activation as compared to dmso injection (p < 0.05 for p38mapk; p > 0.05 for erk and jnk; fig. 5b).",pmc5372348,1,10,38,1,48
72,erk,protein,kinase,,uniprot,p28482,,,stat3,protein,transcription factor,stat3,uniprot,p40763,,,positive,d,phosphorylation,s727,,,,,['3'],nan,nan,"the stat3 serine phosphorylation site is embedded in a conserved pmsp sequence, which contains a mitogen activated protein kinase (mapk) consensus target sequence (pxs/tp) [8]. however, multiple kinases are likely responsible for stat3 s727 phosphorylation, depending on the nature of the activating signal [8]. the best characterized serine kinase responsible for stat3 s727 phosphorylation is erk (more specifically erk2). erk2 interacts with stat3 [13], and treatment of cells with a mek-erk inhibitor (pd98059) blocks stat3 s727 phosphorylation in response to il-2 [14]. these data suggest that erk is a candidate kinase to phosphorylated s727. there are also situations when erk is not activated and yet s727 of stat3 is phosphorylated, probably due to the activity of other serine kinases, including p38, jnk, pkcδ, sek1, mtor, or rac1- or vav-dependent kinases [8]. ras oncogenes activate several serine kinases capable of phosphorylating stat3 on s727; however the serine kinase that is required for stat3 s727 phosphorylation downstream of the ras oncogenes has not been definitively identified.",pmc3843736,1,10,38,1,48
49,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,nucleus,go:0005634,negative,d,inhibition,,,,,human,['653'],nan,nan,robust inhibition of the egfr-ras-erk pathway sensitizes for induced cell death,pmc5127645,1,10,38,1,48
129,mek,protein,,mek,uniprot,p36507,cytoplasm,go:0005737,ras,protein,,ras,uniprot,p01111,plasma membrane,go:0005886,negative,d,inhibition,,lung cancer cell lines,,lung,human,['728'],nan,nan,impact of mek inhibition on the ras signature across 10 lung cancer cell lines. the y-axis shows the ras signature score in drug treated cell lines relative to vehicle treated controls.,pmc2911390,1,10,38,1,48
7,braf,protein,kinase,braf,uniprot,p15056,cytoplasm,go:0005737,erk2,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,activation loop,,b-cell,,human,['982'],nan,nan,"braf mutations are also a characteristic of hairy cell leukemia (hcl), being detected in 95% to 100% of patients with this type of leukemia.17,18 the most common braf mutation leads to the substitution of a valine for glutamic acid at amino acid 600 (v600e) in the kinase domain of the protein. this substitution mimics the phosphorylation of the activation loop, thereby leading to its constitutive activation and phosphorylation of mek1 and mek2, which in turn phosphorylate and activate the effector kinases erk1 and erk2.19 erk proteins target numerous substrates, such as protein kinases, transcription factors, and cytoskeletal or nuclear proteins. moreover, they are able to affect protein functions either by phosphorylating proteins in the cytoplasm or by translocating them into the nucleus where they activate transcription factors that regulate proliferation- and cell survival-associated genes.20",pmc6395334,1,10,38,1,48
135,mek1,protein,kinase,map2k1,uniprot,q02750,cytoplasm,go:0005737,pik3ca,protein,kinase,pik3ca,uniprot,p42336,plasma membrane,go:0005886,negative,d,inhibition,,,,,human,['870'],nan,nan,"analysis of src and mek1/2 inhibitor sensitivity in braf-mutant, ras-mutant, and pik3ca-mutant cell lines.",pmc5833015,1,10,38,1,48
43,da-raf1,protein,,raf1,uniprot,p04049,,,b-raf,protein,,raf1,uniprot,p15056,,,negative,d,regulate,,c2c12,skeletal muscle,,,['506'],nan,nan,"because da-raf1 seems to negatively regulate the b-raf– mek–erk pathway during c2c12 cell differentiation, it may be involved in the induction of differentiation. skeletal muscle cell differentiation entails cell cycle arrest in g0 phase together with muscle-specific gene expression and myotube formation. to examine whether da-raf1 is implicated in the induction of cell cycle arrest, c2c12 cells were transfected with ha–daraf1, and proliferating cells in s phase were detected by the incorporation of brdu in the nuclei. daraf1 expression markedly reduced the ratio of brdu-incorporating cells (fig. 6, a and b).",pmc2064279,1,10,38,1,48
41,da-raf1,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,rb,protein,,rb1,uniprot,p06400,nucleus,go:0005634,negative,d,binding,ras,c2c12,muscle,skeletal muscle,mouse,['517'],nan,nan,"because the amount of da-raf1 was prominently elevated during c2c12 cell differentiation, this elevated amount of da-raf1 seems to be required to achieve the positive regulation of differentiation. indeed, da-raf1 exogenously expressed in c2c12 cells facilitated myogenic differentiation by inducing myogenin and a set of late muscle-specific protein expression as well as the cell cycle arrest. moreover, the knockdown of endogenous da-raf interfered with myogenic differentiation by suppressing cell cycle arrest, myogenin expression, and myotube formation by cell fusion. therefore, da-raf1 is essential for skeletal myocyte differentiation. this essential role of da-raf1 is probably through suppression of the ras–erk pathway because endogenous da-raf1 bound to ras, and the b-raf–mek–erk pathway was suppressed during differentiation. furthermore, overexpressed da-raf1 abrogated erk activation, whereas the knockdown of da-raf facilitated erk activation. the ras–erk pathway negatively regulates muscle-specific gene expression by interfering with the expression of the myod family and mef2 family transcription factors (lassar et al., 1989; winter and arnold, 2000; perry et al., 2001; tortorella et al., 2001). the ras–erk pathway also counteracts the cell fusion and activation of rb (mittnacht et al., 1997; peeper et al., 1997; lee et al., 1999). rb is required for myogenic differentiation by inducing not only the irreversible cell cycle arrest (endo and goto, 1992; schneider et al., 1994; novitch et al., 1996) but also the mef2-dependent expression of late muscle-specific proteins (novitch et al., 1999). the ras–erk pathway causes the inactivation of rb by transactivating cyclin d1 (downward, 1997), which participates in inactivating the phosphorylation of rb by forming the complex with cdk4/6. insulin-like growth factors activate pi3k–akt signaling that induces skeletal muscle myogenesis and hypertrophy (glass, 2003; charge and rudnicki, 2004). thus, suppression of the ras–erk pathway by da-raf1 without affecting ras–pi3k–akt signaling is favorable for skeletal muscle cell differentiation.",pmc2064279,1,10,38,1,48
40,da-raf1,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,phosphorylation,,c2c12,myoblast,,mouse,['515'],nan,nan,"induction of endogenous da-raf1 during c2c12 cell differentiation was accompanied by reduction in the activating phosphorylation levels of mek and erk but not that of akt. in addition, the exogenous expression of daraf1 in v-kras–transformed fibroblasts and in c2c12 myoblasts interfered with the ras–erk pathway but not with ras–pi3k–akt signaling. this is probably because the domains in ras involved in the binding of raf and pi3k p110 are partially overlapping but distinct (rodriguez-viciana et al., 1997; vetter and wittinghofer, 2001). thus, da-raf1 is likely to compete with the binding of raf proteins but not with that of pi3k p110. consequently, da-raf1 may exclusively antagonize the ras–erk pathway but not the signaling pathways of other target proteins. several suppressor proteins of the ras–erk pathway have been identified, including spry/spred, rkip, and imp (kim and bar-sagi, 2004; odabaei et al., 2004; for reviews see ory and morrison, 2004; mason et al., 2006). these proteins antagonize the ras–erk pathway by interacting with a variety of components of the growth factor receptor–ras–erk pathway, but none of them directly bind to ras. thus, the mechanism of da-raf1 to interfere with the ras–erk pathway is unique and distinct from those of the other suppressor proteins.",pmc2064279,1,10,38,1,48
24,brafv600e,protein,mutant,braf,uniprot,p15056,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,activation,,,melanocyte,skin,human,['553'],nan,nan,"since the first description of braf mutations in melanoma (davies et al., 2002) brafv600e, the most predominant mutant, has been shown to constitutively activate erk in melanocytes, and to transform p16/ink4a deficient melanocytes (wellbrock et al., 2004). brafv600e induces melanoma in mice, where this can be accelerated by the absence of p16/ink4a or the pi3k-antagonist pten, or by uv exposure (dankort et al., 2009; dhomen et al., 2009; viros et al., 2014). in line with what has been observed in humans, in zebrafish brafv600e only triggers the formation of benign nevi (patton et al., 2005). however, in zebrafish mutants where a temperature shift lowers levels of functional mitf (possibly compatible with proliferation), brafv600e efficiently induces melanoma (lister et al., 2014; zeng et al., 2015). this further emphasizes the relevance of the braf/mitf connection for melanoma development.",pmc4846800,1,10,38,1,48
4,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,ras,protein,,ras,uniprot,p01116,plasma membrane,go:0005886,positive,d,associated with,,,,,human,['721'],nan,nan,acquired resistance to akt inhibition is associated with increased ras signature. (a) generation of a cell line with acquired resistance to mk-2206 by culturing in increasing drug concentrations over 7 months. (b) cells cultured in vehicle for 7 months remain sensitive to akt inhibition. cells with acquired resistance to mk-2206 show decreased pakt (c) and increased perk (d).,pmc2911390,1,10,38,1,48
20,braf,protein,,braf,uniprot,p15056,plasma membrane,go:0005886,craf,protein,,raf1,uniprot,p04049,plasma membrane,go:0005886,positive,d,dimerization,,,melanoma,,human,['1286'],nan,nan,"while braf inhibitors of both classes stimulate the formation of braf-craf dimers [89,138], type-ii inhibitors are considerably less efficient than type-i inhibitors in stimulating the phosphorylation of downstream targets, i.e., of mek kinases and, henceforth, in activating the mapk pathway. among the possible explanations of this phenomenon, the one that is getting progressively increasing credit is that braf molecules locked in the dfg-out conformation by type-ii inhibitors have poor efficiency in transactivating the kinase activity of the partner protomer [48,135,138,139]. interestingly, type-ii kinase inhibitors are directed toward the most divergent regions among the various kinases, thus having the additional potential advantage of exerting a highly selective, target-specific action. based on previous considerations, type-ii inhibitors should have greater potential than type-i inhibitors in maximizing braf inhibition as single agents or in combined therapies for melanoma treatment. unfortunately, first generation type-ii inhibitors did not hold up to the promises, at least for melanoma treatment.",pmc6472057,1,10,38,1,48
133,mek,protein,,,uniprot,p36507,mitochondria,go:0005739,stat3,protein,,stat3,uniprot,p40763,mitochondria,go:0005739,positive,i,dependent on,s727 phosphorylated state,,,,human,['24'],nan,nan,"taken together, the results shown in figure 2a-c suggest that the activated mek-erk pathway in ras transformed cells is substantially dependent on mitochondrial stat3 in its s727 phosphorylated state. however, transformation by the activated pi3k pathway, while dependent on the expression of stat3, is not mediated by its mitochondrial form. this result is reminiscent of our previous observation that activation of the ral pathway is also dependent on a non-mitochondrial but probably non-nuclear function of stat3 [12].",pmc3843736,1,10,38,1,48
67,er,protein,,,uniprot,p03372,cytoplasm,go:0005737,siah,protein,,siah1,uniprot,q8iuq4,cytoplasm,go:0005737,positive,d,phosphorylation,cytoplasm,,epithelial,,human,['1359'],nan,nan,"original hematoxylin and eosin (h&e) and immunohistochemistry (ihc) slides used for clinical diagnosis collected pre- and post-nst for each patient (1-3 slides per patient) were independently reviewed and scored in a double blind manner by jsw and cfo. slides stained for er, pr, ki67, or siah, were scored using the percentage of positive ihc staining within the tumor. slides with a score discrepancy of greater than 10-percent were then dually re-evaluated by two pathologists together to reach a final consensus score. slides stained for her2 or egfr were scored as 0 (no membrane staining), 1 + (partial membrane staining), 2 + (complete membrane staining in less than 30% of the tumor cells), or 3 + (complete membrane staining in more than 30% of the tumor cells). slides stained for phospho-erk were scored as the percentage of tumor cells with cytoplasmic staining. all histology images presented were captured at 400-fold magnification using a leica compound microscope and leica dc500 digital camera.",pmc5049993,1,1,40,1,41
208,ras,protein,,,uniprot,p01112,plasma membrane,go:0005886,lc3,protein,,,uniprot,q9gzq8,cytoplasm,go:0005737,positive,d,colocalizes,,,,,human,['86'],nan,nan,"the most significant changes occur in the colocalization of the ras protein. while in untreated control, in pd0325901-treated and in senescent eras cells the ras protein is localized under plasma membrane (fig. 9b), no membrane-bound ras has been detected in senescent cells upon 72 h of pd0325901 treatment. immunofluorescence staining using antibodies against ras and lc3 indicates that ras colocalizes with lc3 in the cytoplasm of cells co-treated with nabut and pd0325901 for 24 h. thus, ras re-localizes from the membranes to the cytoplasmic structures in senescent cells upon pd0325901 treatment, where it most possibly fails to function as a regulator of signal transduction and autophagy. thus, in senescent cells pd0325901 does not only inhibit the mer/erk pathway, but also promotes the oncogenic ras re-localization, thereby disrupting its function as an autophagy regulator in senescent eras cells [7, 8].",pmc5723691,1,1,40,1,41
209,ras,protein,,,uniprot,p01112,plasma membrane,go:0005886,myod,protein,transcription factor,,uniprot,p15172,nucleus,go:0005634,negative,i,interference,,,skeletal muscle cell,,,['496'],nan,nan,"the ras–erk pathway also regulates differentiation in a variety of cell types (schramek, 2002). this pathway is essential for ngf-induced neuronal differentiation in pc12 cells (marshall, 1995). in contrast, this pathway, which is activated by serum mitogens or growth factors as well as by oncogenic ras, negatively regulates skeletal muscle cell differentiation (olson et al., 1987; bennett and tonks, 1997). skeletal muscle cell differentiation necessitates irreversible cell cycle arrest in g0 phase, the expression of a battery of muscle-specific genes, and cell fusion to form multinucleated myotubes (endo and nadal-ginard, 1987; lassar et al., 1994). the tumor suppressor protein rb is indispensable for cell cycle arrest (endo and goto, 1992; schneider et al., 1994; novitch et al., 1996), whereas myod family and mef2 family transcription factors bring about the myogenic program by inducing muscle-specific gene expression (black and olson, 1998; tapscott, 2005). the negative regulation of skeletal muscle cell differentiation by the ras–erk pathway is ascribable to interference with the expression or functions of myod and mef2 families (lassar et al., 1989; winter and arnold, 2000; perry et al., 2001; tortorella et al., 2001) and with the activation of rb (mittnacht et al., 1997; peeper et al., 1997; lee et al., 1999). thus, it is reasonable that the deprivation of serum mitogens or growth factors leads to inactivation of the ras–erk pathway and, consequently, results in skeletal muscle cell differentiation. however, detailed mechanisms of this inactivation of the ras–erk pathway have not been fully elucidated.",pmc2064279,1,1,40,1,41
11,braf,protein,kinase,braf,uniprot,p15056,cytoplasm,go:0005737,nras,protein,small gtpase,nras,uniprot,p01111,plasma membrane,go:0005886,positive,d,synergy,d594,,melanoma,,mouse,['297'],nan,nan,"braf variants with mutations in kras or nras may be explained by the experimentally described synergy of kinase-dead braf mutations involving d594 and oncogenic ras. their cooperation in inducing tumor progression, indeed, has been demonstrated in a murine model of melanoma [13], thus confirming the hypothesis that the high frequency of this inactivating mutation (also observed in our mm patient cohort) is incompatible with a random event.",pmc4695180,1,1,40,1,41
14,braf,protein,,braf,uniprot,p15056,cytoplasm,go:0005737,mitf,protein,,mitf,uniprot,o75030,nucleus,go:0005634,negative,d,inhibition,,melanoma,,skin,human,['562'],nan,nan,"resistance mechanisms in mapk-inhibitor treated melanoma. resistance to braf inhibitors can occur through activating nras mutations (*), loss of the ras suppressor nf1, braf amplification or alternative splicing leading to braf truncations (semicircles b*), overexpression or mutation of the mek activators craf, cot/tpl2/map3k8 or mlks as well as mek mutations (*). addition of a mek inhibitor can buffer some of these resistance mechanisms, but eventually enhanced resistance signaling will overcome its effects. while erk is inhibited -particularly in the initial phases of treatment- mitf expression is up-regulated and contributes to drug-tolerance. solid arrows indicate signaling induced by mutant braf, dashed arrows indicate signaling brought about by the various resistance mechanisms.",pmc4846800,1,1,40,1,41
239,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,h-rasv12,protein,,hras,uniprot,p01112,plasma membrane,go:0005886,positive,d,transduction,,mefs,fibroblast,mouse,mouse,['18'],nan,nan,"(a) stat3-/- mefs were stably transduced with h-rasv12 and empty vector (ev) or wild-type stat3 (wt stat3). stat3-/- mefs were also transduced with h-rasv12 effector domain mutants (35s to activate the mek-erk pathway and 40c to activate the pi3k pathway) in addition to a mitochondrially restricted stat3 (35s or 40c+mts stat3) or a mitochondrially restricted phospho-s727 mimetic stat3 (35s or 40c+mts stat3 s/d). 103 cells were plated in media supplemented with 0.3% agar and colonies counted 14 d later. (b) wild type mefs were stably transduced with h-rasv12, h-ras35s or h-ras40c and 103 cells were plated in media supplemented with 0.3% agar and colonies counted 14 d later. (c) stat3-/- mefs were stably transduced with h-rasv12 and wild-type stat3 (h-rasv12+stat3) empty vector (h-rasv12+ev), s727a stat3 (h-rasv12+sa) or s727d stat3 (h-rasv12+sd). 103 cells were plated in media supplemented with 0.3% agar and colonies counted 14 d later. (d) h-rasv12 transformed wild-type (h-ras:stat3+/+), stat3-/- mefs (h-ras:stat3-/-) or h-ras:stat3-/- mefs stably transduced with mitochondrially restricted stat3 (h-ras:mts-stat3) or mitochondrially restricted phospho-s727 mimetic mutant stat3 (h-ras:mts-stat3 s/d) cells were plated in media supplemented with 0.3% agar and the indicated dose of pd0325901 or vehicle (unt) and colonies counted 14 d later. each point represents the mean of biological triplicates, error bars are ±1 standard deviation from the mean. student’s t-test was used to determine significant differences. * denotes p<0.05, ** denotes p<0.01, *** denotes p<0.0001.",pmc3843736,1,1,40,1,41
245,tgf-β1,protein,,,uniprot,p01137,cytoplasm,go:0005737,α-smooth muscle actin (αsma),protein,,acta2,uniprot,p62736,cytoskeleton,go:0005856,positive,d,induction,,rle,epithelial,lung,mouse,['808'],nan,nan,"next, to estimate the transitional state from aec2s to myofibroblasts in rle cells, we analyzed the expression of α-smooth muscle actin (αsma), a marker protein of myofibroblasts [30]. treatment of the cells with tgf-β1 did not affect the amount of αsma for at least 60 min but highly induced αsma during 24–48 h after the treatment (fig 1a). on the other hand, stimulation of the cells with fgf2 along with tgf- β 1 suppressed the induction of αsma even during the 24–48 h period (fig 1b). fgf2 inhibited the tgf- β 1-induced αsma expression in a dose-dependent manner, i.e., 10 ng/ml fgf2 did not suppress the αsma expression, but 50 ng/ml fgf2 reduced the expression to the basal level, and 100 ng/ml fgf2 further reduced the expression (fig 1c). immunofluorescence microscopy located the tgf- β 1-induced αsma to stress fibers in rle cells (fig 1d), indicating that the expressed αsma carries out the contractile function of myofibroblasts [30]. addition of fgf2 dose-dependently decreased the ratio of αsma-expressing cells (fig 1e), and 100 ng/ml fgf2 prominently reduced the ratio of αsma-expressing cells (fig 1d and 1e). these results imply that the low levels of transient activation of mek and erk, which are brought about by tgf- β 1 treatment, do not inhibit emt, but that the fgf2-induced high levels of sustained activation of mek and erk suppress tgf- β 1-induced emt in rle cells.",pmc4440819,1,1,40,1,41
15,braf,protein,,braf,uniprot,p15056,cytoplasm,go:0005737,shp-2,protein,,ptpn11,uniprot,q06124,cytoplasm,go:0005737,positive,d,activation,,,b-cell,,human,['998'],nan,nan,"mutations in genes upstream and downstream of braf were observed in 64% (16/25) of cases. map2k1 mutations have already been described in hcl-variant and conventional hcl with rearranged ighv4-34,34 langerhans cell histiocytosis,35 and pediatric-type follicular lymphoma.36 this mutation, similar to those of braf, leads to activation of the downstream target, erk.36 moreover, we found mutations in additional genes of this pathway, such as map2k2, which encodes mek2, and ptpn11, which encodes shp-2. both these proteins participate in the regulation of the ras-braf-mapk-erk signaling pathway.37 mutations in this pathway seem to be mutually exclusive as only in one case were two different mutations observed simultaneously in the pathway. in this way, oncogene mutations that activate common downstream pathways often occur in a mutually exclusive fashion,38 as has been reported for braf and map2k1 in hcl-variant.34",pmc6395334,1,1,40,1,41
242,tert,protein,catalytic reverse transcriptase subunit,tert,uniprot,o14701,nucleus,go:0005634,ets1,protein,ets transcription factor,ets1,uniprot,p14921,nucleus,go:0005634,positive,d,binding,tert promoter,melanoma,epithelial-like,skin,human,['343'],nan,nan,"the mechanism of telomerase re-activation in cancer had remained elusive until the discovery of frequent mutations in the promoter of the tert gene that encodes the catalytic reverse transcriptase subunit of telomerase. we investigated the regulation of tert expression in melanoma cell lines and our results show that promoter mutations render tert expression dependent on mapk activation due to oncogenic braf or nras mutations. mutations in the tert promoter create binding sites for ets transcription factors. ets1, expressed in melanoma cell lines, undergoes activating phosphorylation by erk at thr38 residue as a consequence of constitutively activated mapk pathway. we demonstrate that ets1 binds on the mutated tert promoter leading to the re-expression of the gene. the inhibition of ets1 resulted in reduced tert expression. we provide evidence that the tert promoter mutations provide a direct link between tert expression and mapk pathway activation due to braf or nras mutations via the transcription factor ets1.",pmc5288173,1,1,40,1,41
19,braf,protein,,braf,uniprot,p15056,,,nras,protein,,nras,uniprot,p01111,,,positive,d,mutations,ras-braf-mapk-erk pathway,,,,cll,['983'],nan,nan,"braf mutations have been recurrently reported in cll patients with a frequency of approximately 3%;21–24 most of these mutations cluster within or near the activation loop. recently, novel cll drivers (nras, kras, nras and map2k1) of the ras-braf-mapk-erk pathway have also been described.9–24 however, the impact of braf mutations and other mutations in the ras-braf-mapk-erk pathway in cll is not well established.",pmc6395334,1,1,40,1,41
22,"braf-mutant, 8505c",protein,braf,braf,uniprot,p15056,cytoplasm,go:0005737,parp,protein,,,uniprot,p09874,nucleus,go:0005634,negative,i,cleavage,,,thyroid,,human,['882'],nan,nan,"a the braf-mutant, 8505c, and ras-mutant, c643, cell lines were analyzed by immunofluorescence for ps6 s235/s236 (green), parp cleavage (red), and dapi (blue) after 24 h of treatment with either dmso, 100 nm trametinib, 100 nm dasatinib, or the combination. b individual cells were analyzed for each treatment group for their intensity levels of s6 phosphorylation. p-s6 low represents signal intensity below half of the average intensity for the dmso treated cells, and p-s6 high represents any cells expressing greater than half of the average intensity for the dmso treated cells. data as means +/− sem (n = 3; student’s t-test; **p < 0.005; ***p < 0.0005). c average percent cleaved parp positive cells for both the p-s6-high and p-s6-low groups were normalized to total treatment group cell count and averaged across three individual experiments. significance is calculated in relation to the dmso treated p-s6 high values. data as means ±sem (n = 3; student’s t-test; *p < 0.05; **p < 0.005)",pmc5833015,1,1,40,1,41
48,egfr,protein,kinase,egfr,uniprot,p00533,plasma membrane,go:0005886,map4k4,protein,kinase,map4k4,uniprot,q9y4k4,cytoplasm,go:0005737,negative,i,downregulation,,h1975,lung adenocarcinoma,lung,human,['1019'],nan,nan,"the most common mechanism for acquired resistance to egfr inhibitors such as erlotinib is the mutation of threonine 790 to a methionine (t790m) in the kinase domain of the egfr gene, which results in increased kinase affinity for atp, thus decreasing the sensitivity to atp‐competitive inhibitors (yun et al., 2008). the current study showed that in t790m‐mutated egfr‐tki‐resistant cell line h1975, downregulation of map4k4 inhibited erk activation in the presence and absence of erlotinib treatment (fig. 3g), implying that map4k4 bypasses egfr to promote erk activation; that is, map4k4 functioned in parallel with egfr to regulate erk activation, which in turn suggests that suppressing erk reactivation through targeting map4k4 in lung adenocarcinoma could be a novel strategy to overcome egfr‐tki resistance.",pmc5467491,1,1,40,1,41
71,erk,protein,kinase,,uniprot,p27361,cytoplasm,go:0005737,mitf,protein,transcription factor,mitf,uniprot,o75030,nucleus,go:0005634,positive,d,phosphorylation,tyr,,melanocyte,skin,human,['549'],nan,nan,"at the center of this transient vs. sustained erk activation is mitf (figure 1a), a tissue specific bhlh-zip transcription factor and fate regulator of the melanocyte lineage, which is a target of erk phosphorylation (hemesath et al., 1998; figure 1a). mitf regulates the expression of genes controlling differentiation (e.g., tyr) proliferation (e.g., cdk2) and survival (e.g., bcl2, bcl2a1) (wellbrock and arozarena, 2015). as erk phosphorylation can increase mitf's transcriptional activity toward tyr (hemesath et al., 1998), transient erk activation can favor differentiation, and in the context of camp signaling this is paralleled by a strong transcriptional up-regulation of the mitf transcript (price et al., 1998). however, erk phosphorylation can also trigger ubiquitin-mediated degradation (wu et al., 2000), and as a result of sustained erk activation mitf protein levels are reduced, a situation that is compatible with proliferation (wellbrock and marais, 2005). nevertheless, because mitf is crucial for cell survival, its expression in proliferative cells is ensured through the erk induced transcription factor brn2 (wellbrock et al., 2008). in summary, the mapk-pathway has stringent control over the melanocyte/melanoma fate-decision regulator mitf, which might explain why this pathway is so particularly critical in the biology of a melanocytic cell and hence in melanoma.",pmc4846800,1,1,40,1,41
152,p38 mapk,protein,kinase,mapk14,uniprot,q16539,cytoplasm,go:0005737,mapkapk-2,protein,kinase,mapkapk2,uniprot,p49137,cytoplasm,go:0005737,positive,d,phosphorylation,,,fibroblast,,human,['477'],nan,nan,"anisomycin-induced p38 mapk activation resulted in a strong activation (phosphorylation) of mapkapk-2 (figure 5a), 12 h after treatment. this activation appeared to be stronger than sa-induced activation. anisomycin-induced p38 mapk activation also led to a decrease in levels of the phosphorylated erk pathway members, similar to that seen in sa-treated cells (figure 5b). furthermore, p38 mapk activation resulted in induction of cell death (figure 5c) within 48 h after anisomycin application, again similar to that seen in sa-treated cells.",pmc4783893,1,1,40,1,41
153,p38 mapk,protein,kinase,mapk14,uniprot,q16539,cytoplasm,go:0005737,mapkapk-2,protein,kinase,,uniprot,p49137,cytoplasm,go:0005737,negative,i,inhibition,,nes2y β-cells,endocrine cell,pancreas,human,['470'],nan,nan,"we also assessed the effect of inhibition of p38 mapk activity, using the specific inhibitor sb202190, on cell growth and viability, phosphorylation of mapkapk-2 (pathway member downstream of p38 mapk), and phosphorylation of erk pathway members (c-raf, mek1/2 and erk1/2) after sa treatment in nes2y β-cells. to assess the efficiency of inhibition, we measured the level of phospho-mapkapk-2.",pmc4783893,1,1,40,1,41
95,jnk,protein,kinase,mapk8,uniprot,p45983,cytoplasm,go:0005737,ptpn1,protein,phosphatase,ptpn1,uniprot,p18031,cytoplasm,go:0005737,negative,d,dephosphorylation,tyrosine,,,,human,['272'],nan,nan,"the jnk pathway kinases transmit signals by continuous phosphorylation of their respective downstream kinase. thus, reduced phosphorylation of jnk by ptpn1 may be the result of inhibition of the upstream kinases, mlk3 or mkk7, or of jnk itself. a ptpn1 phosphatase assay was performed in vitro to ascertain whether mlk3, mkk7, or jnk might be ptpn1 substrates. when phosphorylated mlk3 or mkk7 was incubated with ptpn1, there was no significant change in their phosphorylation status (fig. 3a,b). surprisingly, ptpn1 was found to reduce the tyrosine phosphorylation of jnk but the level of phosphothreonine did not change (fig. 3c). a jnk kinase assay was also performed to investigate the effect of reduced tyrosine phosphorylation on jnk activity. after incubation of phosphorylated jnk with ptpn1, jnk failed to phosphorylate gst-cjun (fig. 3c). this suggests that jnk is a novel ptpn1 substrate, and that ptpn1 reduces the catalytic activity of jnk by reducing tyrosine phosphorylation of jnk in vitro.",pmc5636874,1,1,40,1,41
160,p38 mapk,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,mapkapk-2,protein,,mapkapk2,uniprot,p49137,cytoplasm,go:0005737,positive,d,phosphorylation,substrate,nes2y,,,human,['475'],nan,nan,"effect of p38 mapk overexpression, using transfection with a specific plasmid (vector with p38 mapk) (see “materials and methods”) and the effect of stearic acid (sa) on (a) the level of p38 mapk, phospho-p38 mapk and phospho-mapkapk-2 (substrate of p38 mapk); (b) the level of phospho-c-raf, phospho-mek1/2, phospho-erk1/2 (the erk signaling pathway); and (c) cell growth and viability of nes2y cells. cells transfected with an empty vector (empty vector) represented control cells. after 18 h of incubation (see “materials and methods”) with or without stearic acid (sa) (a,b), the level of individual proteins was determined using western blot analysis and the relevant antibodies (see “materials and methods”). a monoclonal antibody against human actin was used to confirm equal protein loading. the data shown were obtained in one representative experiment from three independent experiments. the fact that the band of p38 mapk in the control samples is not visible here resulted from a large difference in p38 mapk content in control and transfected cells. when assessing cell growth and viability (c), cells were seeded at a concentration of 2 × 104 cells/100 µl of culture medium per well of 96-well plate (see “materials and methods”). the number of living cells was determined after 48 h of incubation with or without sa. each column represents the mean of four separate cultures ± sem. ns (non-significant) when comparing the number of cells incubated with plasmid dna containing p38 mapk (vector with p38 mapk) and cells incubated with empty plasmid dna (empty vector).",pmc4783893,1,1,40,1,41
75,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,cd34+,protein,,cd34,uniprot,p28906,plasma membrane,go:0005886,negative,i,inhibition,,nmri embryos,hematopoietic,,human,['851'],nan,nan,"to find the effect of erk inhibition on engraftment ability of cultured cd34+ cells, the short‐term engraftment capacity of fresh and cultured cd34+ cells was evaluated through in‐utero transplantation of immunodeficient nmri embryos 26, 27, 28. embryos (e11.5–e13.5) were transplanted with 30–50 × 103 primary non‐cultured cd34+‏ cells or their entire progeny following 10‐day culture in the presence or absence of pd. human haematopoietic cell engraftment was assessed in three‐week age mice after one‐week subcutaneous injection of recombinant human growth factors scf (4 ng/g), il3 (4 ng/g) and g‐csf (50 ng/g). as shown in figure 5a, the average human cell engraftment in peripheral blood of the mice transplanted with freshly isolated cd34+ cells was about 0.75 ± 0.22%. the engraftment reduced to less than 0.3 ± 0.2% in mice transplanted with pd‐expanded cd34+ cells. in contrast, treatment of cd34+ cells with cytokine alone resulted in more than twofold (1.7 ± 0.4%) increase in human cell engraftment compared with the freshly isolated cd34+ cells.",pmc5824365,1,1,40,1,41
159,p38 mapk,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,mapkapk-2,protein,,mapkapk2,uniprot,p49137,cytoplasm,go:0005737,negative,i,inhibition,,,,,,['471'],nan,nan,p38 mapk inhibition resulted in a decrease in phospho-mapkapk-2 level (figure 3a) and in an increase of the levels of phosphorylated erk pathway members (figure 3b) 12 h after sa application. p38 mapk inhibition in cells without sa exposure also increased the levels of phosphorylated erk pathway members (figure 3b). cell viability was not significantly affected by the p38 mapk inhibition within the 48-h period after sa treatment (figure 3c).,pmc4783893,1,1,40,1,41
158,p38 mapk,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,mapkapk-2,protein,,mapkapk2,uniprot,p49137,cytoplasm,go:0005737,negative,i,inhibition,,,,,human,['492'],nan,nan,"cells (approximately 5 × 105 cells per sample) were seeded and after a 24-h pre-incubation period (allowing cells to attach) the culture medium was replaced with: (1) a serum-free medium with or without the p38 mapk inhibitor sb202190 (abcam, cambridge, uk) at a desired concentration; (2) a serum-free medium containing 2% bsa with or without the p38 mapk activator anisomycin (sigma aldrich, st. louis, mo, usa) at required concentration; or (3) a serum-free medium containing 2% bsa and sa. the control medium contained only 2% bsa and the vehiculum dimethyl sulfoxide (dmso). after 1 h of inhibitor pre-treatment, 2% bsa with or without sa was added to achieve the required concentrations. after 12 h of incubation, the cells were harvested and lysates were prepared for western blot analysis as described previously [8]. the concentration of inhibitor/activator, which was necessary for efficient p38 mapk inhibition/activation, was determined by testing the effect of several inhibitor/activator concentrations on the level of phosphorylated p38 mapk and/or mapkapk-2 (substrate of p38 mapk). the duration of treatment with the inhibitor/activator was selected based on the time course of activation/inhibition of p38 mapk after sa and sb202190/anisomycin application.",pmc4783893,1,1,40,1,41
157,p38 mapk,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,mapkapk-2,protein,,mapkapk2,uniprot,p49137,cytoplasm,go:0005737,negative,d,silencing,,nes2y,neuronal,embryonic stem cell,human,['467'],nan,nan,"in order to test the involvement of p38 mapk in apoptosis signaling induced by sa in nes2y cells, we assessed the effect of p38 mapk silencing by specific sirna on cell growth and viability after sa treatment. we also tested the effect of p38 mapk silencing on phosphorylation of mapkapk-2 (pathway member downstream of p38 mapk) and phosphorylation of erk pathway members (c-raf, mek1/2 and erk1/2) after sa application. to assess the efficiency of silencing, we measured the level of total p38 mapk and phospho-p38 mapk, respectively.",pmc4783893,1,1,40,1,41
139,mtorc1,protein,complex,,uniprot,p42345,cytoplasm,go:0005737,eras,protein,,,uniprot,p14921,cytoplasm,go:0005737,positive,d,activation,,imr90 er:ras senescent human cells,fibroblast,lung,human,['91'],nan,nan,"despite the high activity of mtorc1 and cell cycle arrest the pd0325901 treated eras cells do not undergo senescence due to the activation of ampk-dependent autophagy that blocks the senescence program. a number of reports indicate that a proper activation of autophagy is required for the establishment of senescence [64-67], while others show that autophagy suppresses senescence [68, 69]. in case of pd0325901-treated eras cells induced to senescence by nabut, the latter scenario may take place, because the forced autophagy could lead to the isolation and degradation of proteins important for the senescence establishment. it has been shown that inhibition of mtorc1 by rapamycin and torin1 in imr90 er:ras senescent human cells reduces the expression of senescence marker sa-β-gal and development of sasp without rescuing cells from the proliferation arrest [70]. in addition to cell cycle arrest, high mtorc1 activity is necessary for the establishment of senescence [23, 25, 71, 72]. although in nabut and pd0325901 co-treated cells these requirements are fulfilled, the senescence is attenuated and cells undergo apoptosis. cells activate tumor suppressor programs such as apoptosis or cellular senescence in response to injury or stress. it has also been reported that senescent cells are resistant to apoptosis [73-75]. the suppression of mek/erk pathway in nabut-senescent eras cells with high torc1 activity initially induces mtorc1-independent autophagy that destabilizes stringent anabolic and catabolic equilibrium of senescent cells resulting in apoptosis.",pmc5723691,1,1,40,1,41
150,p-erk,protein,phosphorylated,mapk1,uniprot,p28482,cytoplasm,go:0005737,gfap,protein,,gfap,uniprot,p14136,cytoplasm,go:0005737,positive,d,phosphorylation,,,astrocyte,brain,human,['1167'],nan,nan,after cci. the results indicated that the number of p-erk-positive gfap,pmc6113736,1,1,40,1,41
119,mapk,protein,mitogen-activated protein kinase,mapk,uniprot,p27361,cytoplasm,go:0005737,sirt1,protein,sirtuin,sirt1,uniprot,q96eb6,nucleus,go:0005634,positive,i,participation,learning and memory,,central nervous system,brain,mouse,['948'],nan,nan,"our previous studies found that mitogen-activated protein kinase (mapk) cascades were involved in the glial activation [13] and resveratrol protects against striatum neuronal apoptosis induced by a nigrostriatal pathway injury in mice via mapk pathway [21]. moreover, some studies showed that sirt1 participates in learning and memory through mapks. sirt1 inhibition reduced the ras/erk1/2 pathway associating with resistance to oxidative damage, suggesting that a correlation between sirt1 and mapk pathways to protect against the central nervous system (cns) injury through yet unknown mechanisms [22–25].",pmc5372348,1,1,40,1,41
109,kras,protein,,kras,uniprot,p01116,,,ncoa3,protein,,ncoa3,uniprot,q15788,,,negative,d,knockdown,,dld-1 cells,colorectal cancer,,human,['1051'],nan,nan,"the clinical response of crcs to the egfr inhibitor cetuximab depends on the kras mutation status [28, 29]. to understand whether foxo3, ncoa3, or tcf7l2 could affect therapy response, we subjected the stable shrna knockdown cell lines to cetuximab. knockdown of ncoa3 and foxo3 caused significantly increased resistance compared to control and kras knockdowns (>100% vs 50%) in dld-1 cells with activating kras mutation (fig. 5a, p < 0.001), but not in dld-1 kraswt/- cells (fig. 5b). the knockdown efficiencies of foxo3 and ncoa3 were 70–80% (additional file 1: figure s8a, b; fig. 2c and d) and the knockdown efficiency of kras was 50% (additional file 1: figure s15).",pmc5755028,1,1,40,1,41
97,jnk,protein,,mapk8,uniprot,p45983,,,gfap,protein,,gfap,uniprot,p14136,,,negative,d,suppression,,primary astrocytes,,,human,['967'],nan,nan,"as shown in fig. 6a, when the erk, jnk, or p38mapk pathway was inhibited at 1 day after il-1β stimulation, the protein level of sirt1 was significantly elevated in the primary astrocytes treated with the inhibitor as compared with the treatment with dmso (p < 0.05 for u0126 and sb203580; p < 0.01 for sp600125). moreover, western blot demonstrated that the inhibition of erk, jnk, or p38mapk pathway significantly suppressed the gfap protein level at 4 day after il-1β stimulation in primary astrocytes (p < 0.01 for all; fig. 6a). however, the dmso control did not show any effect on gfap protein level as compared to the primary astrocytes stimulated with il-1β (p > 0.05, data not shown).",pmc5372348,1,1,40,1,41
151,p-erk,protein,phosphorylated,,uniprot,p27361,"spinal cord, drg","go:0032457, go:0043005",gfap,protein,,gfap,uniprot,p14136,"spinal cord, drg","go:0032457, go:0043005",positive,d,expression,"spinal cord, drg",,neuronal,"spinal cord, drg",human,['1164'],nan,nan,used to detect the expression of p-erk and gfap in the spinal cord and drg so as,pmc6113736,1,1,40,1,41
91,il-1β,protein,cytokine,il1b,uniprot,p01584,extracellular,go:0005615,sirt1,protein,deacetylase,sirt1,uniprot,q96eb6,nucleus,go:0005634,negative,d,reduces expression,,,,,human,['954'],nan,nan,"the results showed that the treatment with il-1β significantly reduced the expression of sirt1 protein from 0.5 h to 4 days. concurrently, the erk, jnk, and p38mapk pathways were activated from 0.5 h and continued until 4 days. in addition, we also found that the p-erk, p-jnk, and p-p38 proteins were at a high level within 1 day (fig. 2a).",pmc5372348,1,1,40,1,41
78,erk,protein,,,uniprot,p27361,"cytoplasm, nucleus","go: 0005737, go: 0005634",ptprs,protein,,ptprs,uniprot,q12984,"plasma membrane, cytoplasm","go:0005886, go:0005737",negative,i,inhibition,cytoplasm,,,,human,['334'],nan,nan,"activation of erk is required for its entry into the nucleus and its nuclear activities47,49,50. we found that the loss of ptprs results in enriched nuclear localization of erk, whereas the ectopic expression of ptprs retains erk primarily in the cytoplasm (fig. 8). thus, ptprs may inhibit erk nuclear localization by negative regulation of erk activation. alternatively, it is also possible that ptprs may directly associate with erk in the cytoplasm by a mechanism involving scaffold protein complexes that are thought to block erk translocation to the nucleus47. ptprs is a membrane receptor ptp that was reported to be proteolytically cleaved into two subunits (the e subunit containing the n-terminal extracellular domain and the p subunit containing the c-terminal phosphatase domains36. in the western blot analysis, we saw both subunits as well as the full-length protein (fig. 8c). thus, ptprs might be associated with erk on the plasma membrane. whether ptprs might be associated with the erk p-subunit in the cytosol is not yet clear.",pmc6006154,1,1,40,1,41
77,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,elk-1,protein,,elk1,uniprot,p19419,nucleus,go:0005634,positive,d,phosphorylation,s383,crc cell lines,epithelial-like,colon,human,['323'],nan,nan,"erk targeted gene regulation and specific phosphorylations. the crc cell lines sw620, km12l4a, hct116 (wt kras) [hct116 (−/+)], and hct116 [hct116 (kras g13d/+)] along with their paired crispr ptprs knockout cell lines were grown and cell extracts were prepared. western blot analysis for phospho-p90rsk (ser 380), dusp6, and c-myc were performed. the ptprs knockout cell line in each pair shows the presence of more protein for each product tested than its parental matching cell line. this effect is consistent even between the wt kras and mutant kras hct116 cells. phosphorylation of elk-1 (s383) and msk1 (t581) are shown. quantitations were determined by normalizing the phosphorylated protein values with the total protein; then dividing the ptprs ko by the crispr control values. the mean and standard deviation are shown.",pmc6006154,1,1,40,1,41
76,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,dusp6,protein,,dusp6,uniprot,q16828,cytoplasm,go:0005737,negative,d,dephosphorylation,thr/tyr,,,kidney,human,['204'],nan,nan,"levels of erk phosphorylation (p-erk) are dictated by the coordinated activities of protein kinases and phosphatases. identical p-erk immunostaining levels described in human ptc regardless of the genetic alteration [4, 5] could be explained by negative feedback control implementing at the p-erk level. thus, we sought to study two dual-specificity (thr/tyr) mapk phosphatases (dusps), dusp5 and dusp6, which belong to this large family known to act as central feedback regulators attenuating mapk signaling. both phosphatases are induced by erk signaling and specifically inactivate erk by dephosphorylation [6–8]. dusp5 localizes in the nucleus [9] while dusp6 is in the cytoplasm [10]. complex post-translational regulation of both phosphatases allows p-erk steady state levels to be tightly regulated. accumulation of dusp5 and dusp6 protein is regulated by rapid proteasomal degradation [6, 11]. accordingly, increasing levels of p-erk will induce dusp5 and dusp6 expression, which in turn will be rapidly degraded.",pmc5599027,1,1,40,1,41
149,p-erk,protein,kinase,mapk1,uniprot,p27361,cytoplasm,go:0005737,gfap,protein,structural protein,gfap,uniprot,p14136,cytoplasm,go:0005737,negative,d,phosphorylation,,,drg,nervous system,unknown,['1170'],nan,nan,number of p-erk–positive gfap cells significantly decreased in the injured drg,pmc6113736,1,1,40,1,41
168,pparγ,protein,,,uniprot,p37231,nucleus,go:0005634,rxr,protein,,,uniprot,p19793,nucleus,go:0005634,positive,d,heterodimerization,ligand-binding domain,"ec109, te10",esophageal cancer,,human,['1381'],nan,nan,"transcriptional regulation by ppars requires heterodimerization with rxr [23]. pparγ and rxrα form a non-symmetric complex, allowing the ligand-binding domain of pparγ to link multiple domains to both proteins [24]. we observed that sirna-mediated knockdown of rxrα in ec109 cells blunted the ability of rgz to repress cell proliferation (figure 1e). to further confirm the role of pparγ, western blot analysis was conducted to detect the expression status of ki67 and pcna. the expression levels of ki67 and pcna were decreased in response to pparγ activation in ec109 and te10 cells (figure 1b and 1d), but increased in the presence of gw9662 or when knockdown of pparγ or rxrα (figure 1f). taken together, all these findings suggest that pparγ is acting as a heterodimer with rxrα to suppress proliferation of esophageal cancer cells.",pmc5190119,1,0.1,39,1,39.1
249,tlr4-,protein,,,uniprot,o00206,plasma membrane,go:0005886,myd88,protein,,myd88,uniprot,q99836,cytoplasm,go:0005737,positive,d,knockdown,,ec109,esophageal carcinoma,esophagus,human,['1390'],nan,nan,"tlr4- and myd88-knockdown ec109 cells were pretreated rgz (20 μm) overnight, followed by stimulation with 10 ng/ml of lps or vehicle for 1 h. *p < 0.05, **p < 0.01. ns: not significant.",pmc5190119,1,0.1,39,1,39.1
5,bcl-xl,protein,,bcl2l1,uniprot,q07817,mitochondria,go:0005739,apaf-1,protein,,apaf1,uniprot,o14727,mitochondria,go:0005739,negative,d,inhibits,,,,,,['1125'],nan,nan,the test was conducted prior to and 1 and 21 days after injury. behavioral,pmc6113736,1,0.1,39,1,39.1
251,α4 integrin chain,protein,,,uniprot,p13612,plasma membrane,go:0005886,hras,protein,,hras,uniprot,p01112,plasma membrane,go:0005886,positive,d,co-immunoprecipitation,,,fibroblast,,human,['904'],nan,nan,"cells were placed on polylysine, collagen type i, or gc1q for 24 hours and at the end of the incubation the cells lysates were immunoprecipitated with the α4 antibody and immunoblotted with anti hras antibody. as expected, the α4 integrin chain was immunoprecipitated from cells adherent on each ligand; however, the ubiquitinated form of hras (40 kda mass) co-immunoprecipitated with the α4 integrin chain only in cells adhered to gc1q (figure 2b). in fact, a band at the expected molecular mass was detected in the lysate and in the unbound cell lysate when probed with anti hras antibody. here, the hrasgtp and hrasgdp ubiquitinated forms cannot be distinguished since the lysates were co-immunoprecipitated and not pulled down for hrasgtp. however, as shown in figure 1c where the amount of hrasgtp-ub is much higher than the amount of hrasgdp-ub, it is very likely that the co-immunoprecipitated hras-ub, in cells adhered to gc1q, is primarily due to the hrasgtp membrane-bound form.",pmc5432316,1,0.1,39,1,39.1
252,α4 integrin chain,protein,wild type,itga4,uniprot,p13612,plasma membrane,go:0005886,hrasgtp,protein,,hras,uniprot,p01112,cytoplasm,go:0005737,negative,d,knocking down,,ht29,epithelial,colon,human,['910'],nan,nan,"the number of colonies grown in agar of ht29 cells transfected with the wild type α4 integrin chain was significantly reduced only when plated in the presence of gc1q (figure 6). the rescue effect by salirasib was not observed under all other conditions, i.e. salirasib and cells transfected with the truncated α4 integrin chain, dmso with both types of cells. this demonstrated that, by knocking down hrasgtp and thus hrasgtp-ub, the signalling produced by α4 integrin engagement loses its antiproliferative cues.",pmc5432316,1,0.1,39,1,39.1
165,parp,protein,substrate,,uniprot,p09874,nucleus,go:0005634,caspase-9,enzyme,executioner,casp9,uniprot,p55211,cytoplasm,go:0005737,positive,d,cleavage,after sa (1 mm) exposure,nes2y,neuronal-like,neural,human,['463'],nan,nan,"we assessed cell viability as well as cleavage of parp (a common marker of apoptosis) and caspase-7, -8 and -9 activation by cleavage after sa (1 mm) exposure, in nes2y cells. sa application resulted in significant induction of cell death within 48 h after sa application (figure 1a), and increased caspase-7, -8, -9 and parp (a substrate of activated executioner caspases) cleavage 18 h after sa application (figure 1b). previously, it was found that there is nearly no activation of caspase-3 in nes2y cells after sa exposure, and that caspase-2 does not play a key role in sa-induced apoptosis [8,29].",pmc4783893,1,0.1,39,1,39.1
166,pbx3,protein,transcription factor,pbx3,uniprot,q99087,nucleus,go:0005634,hoxa9,protein,transcription factor,hoxa9,uniprot,p31260,nucleus,go:0005634,positive,d,cofactor,,,leukemia,,human,['1331'],nan,nan,"pre-b-cell leukemia homeobox (pbx) refers to a family of transcription factors, including pbx1, pbx2 and pbx3. pbx3 has been continuously reported to be associated with tumor growth and progression. li et al. found pbx3 was an important cofactor of hoxa9 in leukemogenesis [14]. hoxa/pbx3 knockdown impaired leukemia growth and sensitized cells to standard chemotherapy [15]. recently, pbx3 was reported to be upregulated in gastric cancer and to regulate tumor cell proliferation [16]. han et al. demonstrated pbx3 promoted migration and invasion of colorectal cancer cells via activation of mapk/erk signaling pathway [17]. however, no data exist concerning the role of pbx3 in the progression of glioma. in addition, as a putative target gene of mir-320, whether mir-320 functions through regulating pbx3 remains unknown.",pmc5609034,1,0.1,39,1,39.1
230,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,gfap,protein,,gfap,uniprot,p14136,cytoplasm,go:0005737,negative,d,transcriptional regulation,,primary astrocytes,astrocyte,brain,human,['957'],nan,nan,"the results revealed that the primary astrocytes transfected with sirt1 appeared to elevate the sirt1 expression and decrease the gfap expression significantly as compared to those transfected with control vector after 24 h (fig. 3a). as shown in fig. 3c. as compared to the transfection with control, the sirt1-transfected astrocytes showed fewer signs of cell hypertrophy and were similar to the control group.",pmc5372348,1,0.1,39,1,39.1
145,nras,protein,,,uniprot,p01111,cytoplasm,go:0005737,ras suppressor nf1,protein,,nf1,uniprot,p21359,cytoplasm,go:0005737,positive,i,loss,,,,,human,['561'],nan,nan,"some of these mechanisms (figure 2) involve activating nras mutations or loss of the ras suppressor nf1 (whittaker et al., 2013), braf amplification or alternative splicing leading to braf truncations (poulikakos et al., 2011; shi et al., 2012) and overexpression or mutation of the mek activators craf, cot/tpl2/map3k8 or mlks (montagut et al., 2008; johannessen et al., 2010; marusiak et al., 2014). braf inhibitor action can also be overcome by mutations in mek itself, and while some of these mutations increase the basal kinase activity of mek, others render the kinase insensitive to mek inhibitors (emery et al., 2009; wagle et al., 2011).",pmc4846800,1,0.1,39,1,39.1
28,cbp,protein,,,uniprot,q15577,,,ach3k18,protein,,,uniprot,q8wz42,,,positive,d,binds,,,,,human,['186'],nan,nan,"membranes were probed with either anti-cbp (sc-369) (santa cruz), anti-ach3k18 (ab1191) (abcam, cambridge, uk), anti-p-erk (9101) (cell signalling, hitchin, uk), anti-erk2 (sc-153) (santa cruz), anti-kras (f234) (santa cruz), anti-acetyl lysine (new england biolabs, frankfurt am main, germany) or anti-α-tubulin (t6074) (sigma-aldrich) primary antibodies. horseradish peroxidase (hrp) conjugated secondary anti-rabbit or anti-mouse antibodies (dako, glostrup, denmark) were used and membranes were developed using an ecl prime detection kit (amersham biosciences, buckinghamshire, uk) followed by exposure to x-ray film. densitometry was carried out using aida image analysis software (raytest, straubenhardt, germany).",pmc5395114,1,0.1,39,1,39.1
30,comp,protein,,comp,uniprot,p49747,,,β2 microglobulin,protein,,b2m,uniprot,p61769,,,negative,i,downregulated expression,,,sos-fibroblasts,,,['940'],nan,nan,"qpcr validation of differentially expressed genes. differential gene expression of rasip1, rbm47, fgf13 (splice variants a and b; c represents a primer set detecting both splice-forms) and comp was studied using qpcr. fold change represents the average difference in expression level of the respective gene after stimulation with ra between the sos-fibroblasts and controls. they were adjusted for the expression of the housekeeping gene β2 microglobulin using the 2−δδct method. black bars depict the fold changes detected with microarray and white bars show the average fold change of triplicate qpcr experiments. fold changes indicating down regulated expression are represented with negative values. error bars represent the standard error of the mean.",pmc3498325,1,0.1,39,1,39.1
31,crebbp,protein,histone acetyltransferase,crebbp,uniprot,q92793,nucleus,go:0005634,camp response element binding protein (creb),protein,transcription factor,creb1,uniprot,p16220,nucleus,go:0005634,positive,d,binding,,,b-cell,,human,['183'],nan,nan,"one gene implicated in all relapse encodes cyclic adenosine monophosphate (camp) response element binding protein (creb) binding protein (crebbp/cbp), a member of the kat3 family of histone acetyltransferases (hat) along with its paralog, ep300. crebbp is involved in a wide range of processes, including camp-dependent signaling, histone acetylation, acetylation-mediated activation or inactivation of non-histone proteins, wnt signaling, cell cycle control, ubiquitination, dna damage repair and antigen presentation.6–12 germline mutations in crebbp cause rubinstein-taybi syndrome, which is characterized by developmental defects and an increased susceptibility to malignancies.13,14 a study by mullighan et al. identified that 18% of relapsed childhood all cases were crebbp mutant,15 and further studies showed enrichment in the high hyperdiploid (hhd) (51–68 chromosomes) and hypodiploid cytogenetic subgroups, seen in approximately 30% of cases.16–18",pmc5395114,1,0.1,39,1,39.1
33,crebbp,protein,,crebbp,uniprot,q92793,nucleus,go:0005634,h3k18,protein,histone,h3-3a,uniprot,p68431,chromatin,go:0000785,negative,d,acetylation,h3k18,bcp-all,b-cell,,human,['189'],nan,nan,stable crebbp knockdown in bcp-all cells is associated with reduced acetylation of h3k18 and an expression profile linked to the gr,pmc5395114,1,0.1,39,1,39.1
38,cxcr4,protein,receptor,cxcr4,uniprot,p61073,cell membrane,go:0005886,cd34,protein,stem cell marker,cd34,uniprot,p28906,membrane,go:0016020,positive,d,migration,transwell,cd34+ expanded cells,stem cell,bone marrow,human,['852'],nan,nan,"(a) percentage of human cd45 positive cells in peripheral blood of newborn mice after one‐week treatment with human haematopoietic growth factors [scf (4 ng/g), il3 (4 ng/g) and g‐csf (50 ng/g)]. (b) immunocytochemistry to identify human cells in the bone marrow of newborn mice, dapi stains nucleus (blue), (c) human nuclear antibody (red). (d) cxcr4 gene expression in pd‐expanded cd34+ cells relative to the positive control group detected by quantitative real‐time pcr (n = 3). (e) percentage of cd34+ expanded cells migrated through the transwell in response to sdf‐1 as a chemoattractant factor.",pmc5824365,1,0.1,39,1,39.1
144,nm23/ndpk,protein,,,uniprot,p15531,,,ksr1,protein,,,uniprot,o15530,,,positive,d,phosphorylation,ser392,,,,,['47'],nan,nan,"regulation of ksr: nm23/ndpk is a factor, which is able to phosphorylate ksr1 on ser392",pmc4020307,1,0.1,39,1,39.1
172,ptpn1,protein,,,uniprot,p18031,,,leptin,protein,,,uniprot,p41159,,,negative,d,dephosphorylates,,,,,human,['266'],nan,nan,"ptpn1 was first discovered in isolates from human placental tissues34 and the three-dimensional structure of ptpn1 has been subsequently identified35. previous studies have shown that ptpn1 directly dephosphorylates insulin receptor (ir) and insulin receptor substrates (irs), which results in downregulation of insulin signaling36,37. for example, ptpn1 deficient mice show increased insulin sensitivity38,39. ptpn1 also dephosphorylates activated stat3 and jak2, and regulates leptin signaling40–42. ptpn1 contains a signature ptp family motif [i/v]hcxxgxxr[s/t] located beside the wpd loop, the q loop, and the tyr loop43. the wpd loop contains a conserved acidic residue (asp181 in ptpn1) that plays an important role in protonation of the tyrosyl leaving group of a substrate. mutation of asp181 in ptpn1 results in the suppression of ptpn1 catalytic activity; however, the affinity of ptpn1 for substrates is maintained. thus, ptpn1 d181a acts as a ‘substrate trap’ that exerts a dominant-negative effect43,44. the structural approach also provided further analysis of potential substrates of ptpn1 in vivo",pmc5636874,1,0.1,39,1,39.1
175,ptpn1,protein,,ptpn1,uniprot,p18031,cytoplasm,go:0005737,mlk3,protein,,,uniprot,q16584,cytoplasm,go:0005737,negative,d,dephosphorylation,,293 t,epithelial-like,kidney,human,['283'],nan,nan,"the catalytic activity of both ptpn1 and ptpn1 d181a was measured using pnpp. to identify ptpn1 substrates, phosphatase assays were performed with bacterially expressed ptpn1. ha-mlk3 was expressed in 293 t cells, and then purified using anti ha-agarose (sigma). to purify phospho-mkk7, gst-mkk7 was co-expressed with his-mlk3 in escherichia coli. to generate phosphorylated jnk, gst-jnk was co-expressed with his-mkk7, (a constitutively activated mutant form of mkk7, harboring ser-271, thr-275, and ser-277 mutations to glu) in escherichia coli. phosphorylated proteins were incubated with purified his-ptpn1 (30 min, 37 °c). protein phosphorylation levels were detected by immunoblot analysis.",pmc5636874,1,0.1,39,1,39.1
93,il3,protein,,il3,uniprot,p08700,extracellular space,go:0005615,g‐csf,protein,,csf3,uniprot,p09919,extracellular space,go:0005615,positive,d,injection,subcutaneous,newborn mice,hematopoietic,bone marrow,mouse,['840'],nan,nan,"newborn mice were expanded with subcutaneous injections of human il3 (4 ng/g), scf (4 ng/g) and g‐csf (50 ng/g), three times a week beginning at 2 weeks of age. for analysing haematopoietic engraftment, 1 week later, the peripheral blood samples of newborn mice were labelled with pe anti‐human cd45 (bd pharmingen™). to delete non‐specific background signal, the cells were stained with the appropriate isotype‐matched control and at least 105 events were acquired on a partec pas system. data were analysed with flomax software. moreover, bone marrow smears were prepared, air‐dried and fixed with ice‐cold acetone and subjected for human nuclear antigen staining using specific antibody.",pmc5824365,1,0.1,39,1,39.1
90,hrasgtp,protein,,,uniprot,p01112,plasma membrane,go:0005886,α4 integrin chain,protein,,,uniprot,p13612,plasma membrane,go:0005886,positive,d,linked,,ht29 and sw480,epithelial,colon,human,['905'],nan,nan,"to demonstrate if this pathway (hrasgtp → hrasgtp-ub → perk1/2) was directly linked to the α4 integrin chain, we selected the ht29 and sw480 cell lines that were negative for α4β1 and positive for α2β1 integrin (figure 3a). both cell lines were then stably transfected with either the wild type or an α4 integrin chain deleted of the intracytoplasmic sequences (figure 3b). for the following experiments only cells that resulted at least 95% positive for the expression of the α4 integrin chain were used. both ht29 and sw480 transfected with either the wild type or the deleted α4 form were able to adhere to gc1q although ht29 cells were more efficient than sw480 cells as the percentage of adhesion to gc1q was 90% and 60%, respectively (figure 3c and 3d). thus, for the following experiments we selected ht29 cells. several clones transfected with either the wild type or the mutant α4 integrin chain were selected and the clones in which the α4 cell surface expression was more stable were further used. we measured the proliferative capacity of the transfected cells grown on collagen type i or emilin1/gc1q and found that the proliferation rate (measured as either normalized cell index or doubling time) of the cells transfected with either the wild type or the mutated α4 form was very similar on collagen type i. on the contrary, the proliferation rate was significantly lower on the full length emilin1 or gc1q in cells transfected with the wild type α4 integrin chain compared to cells transfected with the deleted form in which the proliferation was not affected at all (figures 4a and 4b). these results show that the downstream signaling leading to reduced proliferation following α4β1-dependent cell adhesion to the emilin1/gc1q ligand depended on a fully functional α4 integrin chain. to link the proliferative and clonogenic capacity to the α4β1 integrin-dependent hras activity we placed ht29 transfected clones in agar in the presence or in the absence of soluble gc1q. whereas the colonies of the cells transfected with the wild type α4 integrin chain were significantly less in the presence of gc1q (figure 4c), the colonies of ht29 transfected with the mutant α4 integrin grew to the same number under all the experimental conditions (figure 4d).",pmc5432316,1,0.1,39,1,39.1
84,gfap,protein,,,uniprot,p14136,cytoplasm,go:0005737,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,negative,d,downregulation,,,astrocyte,brain,human,['944'],nan,nan,"gfap level and morphological hypertrophy of astrocytes are elevated after injury in vitro or in vivo. furthermore, the expressions of phosphorylated extracellular regulated protein kinases (p-erk), phosphorylated c-jun n-terminal kinase (p-jnk), and phosphorylated p38 activation (p-p38) are upregulated, but the sirt1 expression is downregulated. overexpression of sirt1 significantly increases the p-erk expression and reduces the p-jnk and p-p38 expressions. inhibition of erk, jnk, or p38 activation respectively with their inhibitors significantly elevated the sirt1 expression and attenuated the astrocyte activation. both the overproduction of sirt1 and inhibition of erk, jnk, or p38 activation can alleviate the astrocyte activation, thereby improving the neurobehavioral function according to the modified neurological severity scores (mnss) and balance latency test.",pmc5372348,1,0.1,39,1,39.1
82,gapdh,protein,,gapdh,uniprot,p04406,cytoplasm,go:0005737,nfat,protein,,nfatc1,uniprot,o95644,nucleus,go:0005634,positive,d,phosphorylation,,,t-cell,,human,['950'],nan,nan,"in the quantitative statistics of western blot, the detection of gray value in p-erk/jnk/p-38 bands used computer-assisted imaging analysis system (bio-rad) by drawing a rectangle with the same size to detect gray value of p-erk/jnk/p-38 proteins. because the total erk/jnk/p-38 level did not change after the nerve injury, the gray level ratio of p-erk and t-erk, p-jnk and t-jnk, p-p38 mapk and p38 mapk, and the ratios of sirt1 and gfap to gapdh were used as the relative expression level of the target protein. all the experiments were repeated for at least three times. data are presented as the mean and standard error of the mean (mean ± sem). the comparison of different groups was analyzed by one-way anova followed by the post hoc bonferroni evaluation using graphpad prism5. differences were termed statistically significant at p < 0.05.",pmc5372348,1,0.1,39,1,39.1
80,ets1,protein,transcription factor,ets1,uniprot,p14921,nucleus,go:0005634,nras,protein,gtpase,nras,uniprot,p01111,plasma membrane,go:0005886,positive,d,activation,,,melanoma,skin,human,['352'],nan,nan,our results have important implications for understanding the mechanism through which telomerase is reactivated in tumors cells. we provide evidence that tert promoter mutations via ets1 form a direct relationship between tert expression and mapk pathway activation through braf or nras mutations. this probably participates in cellular immortalization during melanoma development.,pmc5288173,1,0.1,39,1,39.1
253,α4β1 integrin,protein,,,uniprot,p16144,plasma membrane,go:0005886,hras,protein,gtpase,hras,uniprot,p01112,plasma membrane,go:0005886,positive,i,di-ubiquitination,,,b-cell,,human,['903'],nan,nan,"to determine if the downstream consequences of cell adhesion to gc1q were dependent on a mechanism specifically due to the ligation of the α4β1 integrin, we compared the extent of di-ubiquitinated hrasgtp in cells adherent to gc1q to that detected in cells adherent to collagen type i that uses a different integrin as cellular receptor. as depicted in figure 1c both the anti ubiquitin antibody as well as the anti hras antibody recognized proteins whose migration corresponded to the hrasgtp di-ubiquitinated form. hrasgtp-ub was 10 times less in cells adherent to polylysine as well as to collagen type i compared to gc1q (figure 1c), suggesting that the α4-dependent signaling was qualitatively/quantitatively distinct and specific. accordingly, while the ratio of hrasgtp-ub/hrasgdp-ub was about 0.5 in cells adherent to either polylysine or collagen type i, this ratio was 10-fold in cells adherent to gc1q, indicating that in α4-dependent cell adhesion there is a specific switch from rasgdp to rasgtp.",pmc5432316,1,0.1,39,1,39.1
